Product :  AMG 592  
Protocol Number:  20170103  
Date:  25 June 2020  Page 1 of 97 
CONFIDENTIAL   Title Page 
Protocol Title:  A Randomized, Double -bl ind, Placebo -controlled 
Phase 1b Study to Evaluate the Safety, 
Tolerability, Pharmacokinetics, Pharmacodynamics, and 
 Immunogenicity of 
Multiple Asce nding Subcutaneous Doses of 
AMG  592 in Subjects With Systemic Lupus 
E
rythematosus 
Short Protocol Title:  Safety , T olerability, Pharmacokinetics, 
Pharmacodynamics and Immunogenicity  of 
AMG  592 in Subjects with Systemic Lupus 
E
rythematosus  
Protocol Number:  20170103  
Investigational Product:  AMG 592  
Trade Name:  Not applicable 
Sponsor  Na me of Sponsor:  Amgen, Inc.  
Address:  One Amgen Center Drive,  
Thousand Oaks, CA 91320, USA  
Telephone Number:  +1 (805) 447 -1000  
Key 
Spons
or 
Contact  Name:  , MD  
A
ddress:  One Amgen Center Drive,  
Thousand Oaks, CA 91320, USA  
Telephone Number:  ; 
Email Address:   
EudraCT Number:  2017 -002564 -40 
N
CT Number:  [STUDY_ID_REMOVED] 
Protocol Date:  Document Version  Date 
Original  13 A ugust 2017  
Amendment 1 26 J uly 2018  
Amendment 2 12 June 2019  
Amendment 3 18 November 2019  
Amendment 4 06 February 2020  
Superseding Am
endment 4 24 February 2020  
A
mendment 5  23 April 2020 
Superseding Ame
ndment  5 25 June 2020 
 
Approved  
  AMGEN~ 

Product :  AMG 592  
Protocol Number:  20170103  
Date:  25 June 2020  Page 2 of 97 
CONFIDENTIAL   Version/Date:  Data Element 
Standards Version   
5.
0  
 
Confidentiality Notice  This document contains confidential information of Amgen Inc. 
This document must not be disclosed to anyone other than the site study staff and 
members of the institutional review board/independent ethics committee/institutional scientific review board or equivalent. 
The information in this document cannot be used for any purpose other than the 
evaluation or conduct of the clinical investigation without the prior written consent of 
Amgen Inc. 
If you have questions regarding how this document may be used or shared, call the 
Amgen Medical Information number:  US
  sites, 1- 800-77-AMGEN; Canadian sites, 
1-866-50-AMGEN; all other countries call 1-800 -772 -6436; Amge n’s general number 
in the US, 1-805-447-1000. 
Approved  
  AMGEN~ 
Product :  AMG 592  
Protocol Number:  20170103  
Date:  25 June 2020  Page 3 of 97 
CONFIDENTIAL   Investigator's Agreement:  
I have read the attached protocol entitled A Randomized, Double-blind, 
Placebo-controlled Phase 1b Study to Evaluate the Safety, Tolerability, 
Pharmacokinetics, Pharmacodynamics, and Immunogenicity of M ultiple 
Ascending Subcutaneous Doses of  AMG 592 in Subjects with Systemic Lupus 
Erythematosus , dated 25 June 2020, and agree to abide by all provisions set forth 
therein.   
I agree to comply with the International Council for Harmonisation (ICH) Tripartite 
Guideline on Good Clinical Practice (GCP), Declaration of Helsinki, and applicable 
national or regional regulations/guidelines.   
I agree to ensure that the confidential information contained in this  document will not be 
used for any purpose other than the evaluation or conduct of the clinical investigation 
without the prior written consent of Amgen Inc. 
 
_______________________________ Signature  _______________________________ ____________________________ 
Name of Investigator  Date (DD Month YYYY ) 
 
Approved  
  AMGEN~ 
Product :  AMG 592  
Protocol Number:  20170103  
Date:  25 June 2020  Page 4 of 97 
CONFIDENTIAL   Table of Contents 
Table of Contents  .............................................................................................................. 4  
1. Protocol Synopsis ..................................................................................................... 9  
2. Study Schema and Schedule of Activities  .............................................................. 14 
2.1 Study Schema  ............................................................................................ 14 
2.2 Schedule of Activities  ................................................................................. 15 
3. Introduction  ............................................................................................................ 19 
3.1 Study Rationale .......................................................................................... 19 
3.2 Background  ................................................................................................ 19 
3.2.1 Disease  ....................................................................................... 19 
3.2.1.1 Interleukin 2 and T Regulatory Cells in 
Systemic Lupus Erythematous  ................................ 19 
3.2.1.2 Low Dose Interleukin 2 in Inflammatory Disease  .................................................................... 20 
3.2.1.3 Clinical Experience With Low Dose IL-2 in Systemic Lupus Erythematosus  ............................... 21 
3.2.2 Amgen Investigational Product Background:  
AMG 592 .................................................................................... 21 
3.2.2.1 Toxicology  ................................................................ 22 
3.2.2.2 Human Exposure ..................................................... 22 
3.3 Risk Assessment  ........................................................................................ 23 
4. Objectives, Endpoints and Hypotheses  .................................................................. 24 
4.1 Objectives and Endpoints  ........................................................................... 24 
4.2 Hypotheses  ................................................................................................. 24 
5. Study Design .......................................................................................................... 25 
5.1 Overall Design ............................................................................................ 25 
5.2 Number of Subjects  .................................................................................... 27 
5.2.1 Replacement of Subjects  ............................................................ 27 
5.2.2 Number of Sites  .......................................................................... 27 
5.3 End of Study  ............................................................................................... 27 
5.3.1 End of Study Definition ............................................................... 27 
5.3.2 Study Duration for Subjects  ........................................................ 28 
5.4 Justification for Investigational Product Dose ............................................. 28 
5.5 Patient Input on Study Design  ....................................................................  29 
6. Study Population ....................................................................................................  29 
6.1 Inclusion Criteria .........................................................................................  29 
6.2 Exclusion Criteria  ........................................................................................  30 
6.3 Lifestyle Restrictions  ...................................................................................  34 
6.3.1 Alcohol and Tobacco  ..................................................................  34 
6.3.2 Activ
ity ........................................................................................ 34 
Approved  
  AMGEN~ 
Product :  AMG 592  
Protocol Number:  20170103  
Date:  25 June 2020  Page 5 of 97 
CONFIDENTIAL   6.4 Subject Enrollment ..................................................................................... 34 
6.5 Screen Failures  .......................................................................................... 35 
7. Treatments  ............................................................................................................. 35 
7.1 Treatment Procedures  ................................................................................ 36 
7.1.1 Investigational Products  ............................................................. 36 
7.1.1.1 Amgen Investigational Product:  AMG 592 .............. 36 
7.1.2 Non-investigational Products  ...................................................... 36 
7.1.3 Medical Devices  ......................................................................... 37 
7.1.4 Other Protocol -required Therapies  ............................................. 37 
7.1.5 Other Treatment Procedures  ...................................................... 37 
7.1.6 Product Complaints  .................................................................... 37 
7.1.7 Excluded Treatments, Medical Devices, and/or 
Procedures During Study Period  ................................................ 37 
7.2 Method of Treatment Assignment .............................................................. 38 
7.3 Blinding  ....................................................................................................... 38 
7.3.1 Site Personnel Access to Individual Treatment 
Assignments  ............................................................................... 38 
7.3.2 Access to Individual Subject Treatment Assignments 
by Amgen or Designees ............................................................. 39 
7.4 Dose Modification  ....................................................................................... 39 
7.4.1 Dose -cohort Study Escalation/De-escalation and 
Stopping Rules  ........................................................................... 39 
7.4.1.1 Dose Level Review Meetings  ................................... 39 
7.4.1.2 Dose Cohort Stopping Rules  ................................... 39 
7.4.2 Dosage Adjustments, Delays, Rules for Withholding or 
Restarting, Permanent Discontinuation ...................................... 41 
7.4.2.1 Amgen Investigational Product:  AMG 592 .............. 41 
7.4.3 Hepatotoxicity Stopping and Rechallenge Rules  ........................ 41 
7.5 Preparation/Handling/Storage/Accountability  ............................................. 41 
7.6 Treatment Compliance ............................................................................... 41 
7.7 Treatment of Overdose  ............................................................................... 41 
7.8 Prior and Concomitant Treatment .............................................................. 41 
7.8.1 Prior Treatment ........................................................................... 41 
7.8.2 Concomitant Treatment .............................................................. 41 
7.8.2.1 SLE Therapies  ......................................................... 41 
7.8.2.2 Corticosteroids  ......................................................... 42 
8. Discontinuation Criteria  .......................................................................................... 42 
8.1 Discontinuation of Study Treatment ........................................................... 42 
8.2 Discontinuation From the Study  ................................................................. 43 
8.2.1 Reasons for Removal From Washout, Run-in or 
Invasiv
e Procedures  ................................................................... 43 
8.2.2 Reasons for Removal From Study  ............................................. 43 
8.3 Lost to Follow -up ........................................................................................ 44 
Approved  
  AMGEN~ 
Product :  AMG 592  
Protocol Number:  20170103  
Date:  25 June 2020  Page 6 of 97 
CONFIDENTIAL   9. Study Assessments and Procedures ..................................................................... 44 
9.1 General Study Periods  ............................................................................... 44 
9.1.1 Screening, Enrollment and/or Randomizati on ............................ 44 
9.1.2 Treatment Period ........................................................................ 45 
9.1.3 Follow -up/Safety Follow-up/End of Study  ................................... 45 
9.2 Description of General Study Assessments and Procedures  ..................... 46 
9.2.1 General Assessments  ................................................................ 46 
9.2.1.1 Informed Consent  .................................................... 46 
9.2.1.2 Demographics  .......................................................... 46 
9.2.1.3 Medical History  ........................................................ 46 
9.2.1.4 Physical Examination ............................................... 46 
9.2.1.5 Physical Measurements  ........................................... 46 
9.2.1.6 Substance Abuse History  ......................................... 46 
9.2.2 Efficacy Assessments  ................................................................. 47 
9.2.2.1 Systemic Lupus Erythematosus Disease 
Activity Index -2000  ................................................... 47 
9.2.3 Safety Assessments  ................................................................... 47 
9.2.3.1 Adverse Events  ........................................................ 47 
9.2.3.2 Vital Signs  ................................................................ 50 
9.2.3.3 Electrocardiograms  .................................................. 50 
9.2.3.4 Home Healthcare Services  ...................................... 51 
9.2.4 Clinical Laboratory Assessments  ............................................... 52 
9.2.4.1 Pregnancy Testing  ................................................... 53 
9.2.4.2 Human Immunodeficiency Virus, Hepatitis  B Surface Antigen, and 
Hepatitis  C Antibody  ................................................ 53 
9.2.4.3 Prespecified Biomarker Assessments  ..................... 54 
9.2.5 Pharmacokinetic Assessments  ................................................... 54 
9.2.6 Pharmacodynamic Assessments  ............................................... 54 
9.2.7 Pharmacogenetic Assessments  ................................................. 54 
9.2.8 Antibody Testing Procedures  ..................................................... 55 
9.2.9 Biomarker Development  ............................................................. 55 
9.2.10 Other Assessments  .................................................................... 56 
9.2.10.1 Tuberculosis Testing  ................................................ 56 
9.2.10.2 Peripheral Blood Mononuclear Cell ......................... 56 
10. Statistical Considerations  .......................................................................................  56 
10.1 Sample Size Determination ........................................................................  56 
10.2 Analysis Sets, Subgroups, and Covariates  ................................................ 57 
10.2.1 Analysis Sets  ................................ ..............................................
 57 
10.2.1.1 Safety Analysis Set .................................................. 57 
10.2.1.2 Pharmacokinetic Concentration Analysis Set ............................................................................ 57 
10.2.1.3 Pharmacokinetic Parameter Analysis Set ................ 57 
Approved  
  AMGEN~ 
Product :  AMG 592  
Protocol Number:  20170103  
Date:  25 June 2020  Page 7 of 97 
CONFIDENTIAL   10.2.1.4 Pharmacodynamic Analysis Set .............................. 57 
10.2.2 Covariates  .................................................................................. 57 
10.2.3 Subgroups  .................................................................................. 57 
10.2.4 Handling of Missing and Incomplete Data .................................. 58 
10.3 Statistical Analyses  ..................................................................................... 58 
10.3.1 Planned Analyses  ....................................................................... 58 
10.3.2 Methods of Analyses  .................................................................. 58 
10.3.2.1 General Considerations ........................................... 58 
10.3.2.2 Efficacy Analyses  .................................................... 58 
10.3.2.3 Safety Analyses  ....................................................... 58 
10.3.2.4 Other Analyses  ........................................................ 59 
11. References  ............................................................................................................. 61 
12. Appendices  ............................................................................................................ 63 
Appendix 1.  List of Abbreviations and Definitions of Terms  .................................. 64 
Appendix 2.  Clinical Laboratory Tests  ................................................................... 67 
Appendix 3.  Study Governance Considerations .................................................... 69 
Dose Level Review Meetings and Data Review Team  ............................... 69 
Regulatory and Ethical Considerations  ...................................................... 70 
Informed Consent Process  ......................................................................... 71 
Data Protection/Subject Confidentiality  ...................................................... 72 
Publication Policy  ....................................................................................... 73 
Investigator Signatory Obligations .............................................................. 74 
Data Quality Assurance  .............................................................................. 74 
Source Documents  ..................................................................................... 75 
Study and Site Closure  ............................................................................... 76 
Compensation ............................................................................................ 77 
Appendix 4.  Safety Events:  Definitions and Procedures for Recording, 
Evaluating, Follow-up and Reporting .......................................................... 78 
Definition of Disease-related Event  ............................................................ 78 
Definition of Adverse Event ........................................................................ 78 
Definition of Serious Adverse Event ........................................................... 79 
Recording Adverse Events, Disease- related Events 
(if applicable), and Serious Adverse Events  ............................... 80 
Evaluating Adverse Events and Serious Adverse Events  .......................... 80 
Reporting of Serious Adverse Event  .......................................................... 82 
Appendix 5.  Contraceptive Guidance and Collection of Pregnancy and 
Lactation Information ..................................................................................  86 
Definition of Females of Childbearing Potential .......................................... 86 
Collection of Pregnancy Information ........................................................... 87 
Collection of  Lac
tation Information ............................................................. 89 
Appendix 6.  Sample Storage and Destruction  ...................................................... 92 
Approved  
  AMGEN~ 
Product :  AMG 592  
Protocol Number:  20170103  
Date:  25 June 2020  Page 8 of 97 
CONFIDENTIAL   Appendix 7.  Hepatotoxicity Stopping Rules:  Suggested Actions and 
Follow -up Assessments and Study Treatment Rechallenge 
Guidelines  ................................................................................................... 94 
Criteria for Withholding and/or Permanent Discontinuation of 
Amgen Investigational Product and Other 
Protocol -required Therapies due to Potential 
Hepatotoxicity  ............................................................................. 94 
Criteria for Rechallenge of Amgen Investigational Product and 
Other Protocol -required Therapies After Potential 
Hepatotoxicity  ............................................................................. 95 
Drug -induced Liver Injury Reporting and Additional 
Assessments .............................................................................. 96 
 
List of Tables 
Table 2-1.  Schedule of Activities:  Screening and Treatment Period ............................. 15 
Table 2-2.  Schedule of Activiti es Follow -up ................................................................... 18 
... 23 
... 25 
... 28 
Table 7-1.  Dose Cohort Stopping Rules  ........................................................................ 40 
Table 12-1.  Analyte Listing ............................................................................................. 67 
Table 12-2.  Conditions for Withholding and/or Permanent Discontinuation of 
Amgen Investigational Product and Other Protocol -required 
Therapies due to Potential Hepatotoxicity  ............................................... 95 
 
List of Figures 
Figure 2-1.  Study Schema  ............................................................................................. 14 
Figure 12-1.  Sample Electronic Serious Adverse Event Contingency Form  .................. 83 
Figure 12-2.  Pregnancy and Lactation Notification Worksheet ...................................... 90 
 
Approved  
  AMGEN~ 

Product :  AMG 592  
Protocol Number:  20170103  
Date:  25 June 2020  Page 9 of 97 
CONFIDENTIAL   1. Protocol Synopsis 
Protocol Title:   A Randomized, Double-blind, Placebo-controlled Phase 1b Study 
to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and 
Immunogenicity of Multiple Ascending Subcutaneous Doses of  AMG 592 in 
Subjects with Systemic Lupus Erythematosus  
Short Protocol Title:   Safety, Tolerability, Pharmacokinetics, Pharmacodynamics 
and Immunogenicity  of AMG 592 in Subjects with Systemic Lupus Erythematosus  
Study Phase:   1b 
Indication:   Systemic Lupus Erythematosus  
Rationale 
This is a double-blind, placebo-controlled, multicenter , phase 1b study to evaluate the 
safety, tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and 
immunogenicity  of AMG 592 in subjects with systemic lupus erythematosus (SLE ).  
This information will be used to determine the recommended phase 2  dose(s).  
Objective(s)/Endpoint(s) 
 
Approved  
  AMGEN~ 
Product :  AMG 592  
Protocol Number:  20170103  
Date:  25 June 2020  Page 10 of 97 
CONFIDENTIAL   Objectives Endpoi nts 
Primary  
• To evaluate the safety and tolerability 
of
 subcutaneous (SC) dose 
administrations of AMG  592 in subjects 
with systemic lupus erythematosus 
(SLE)  • Treatment -emergent adverse events  
• Clinically significant changes in physical 
examinations, vital signs, and laboratory 
safety tests  
Secondary 
• To characterize the ph armacokinetic 
(PK) profile following treatment with 
AMG  592 • AMG 592 serum concentration and PK parameters including, but not limited to, maximum observed concentration (C
max), the 
time of maximum observed concentration (T
max), and area under the concentration -time 
curve over a dosing interval (AUC tau) after 
the first and last doses  
• To evaluate anti -AM G 592 antibody 
formation  • Incidence of anti -AMG  592 antibodies  
• Cross -reactivity of anti -AMG  592 antibodies 
with human interleukin -2 (IL-2) 
• Incidence of anti -AMG 592 and anti -IL 2 
neutralizing antibodies  
Exploratory  
• To explore the effect of 
t
reatment with AMG 592 on 
measures of inflammation at various time points  • Change from baseline in anti -double 
stranded DNA (anti -dsDNA), and C3 
and C4 complements at all time points 
collected  
• To explore the effect of 
t
reatment with AMG 592 on 
measures of disease activity at various time points  • SLEDAI -2K score and change from 
baseline at all time points collected  
• To evaluate the immunological 
ef
fects of AMG 592  • Fold changes from baseline of Treg, 
Tcon, and NK absolute cell counts 
(cells/µL) after AMG  592 
a
dministration 
• Changes in Treg/Tcon ratio after AMG  592 administration  
 
Hypotheses 
AMG 592 will be safe and well tolerated in subjects with SLE. 
Overall Design This phase 1b study is a double-blind, placebo- controlled, multiple ascending dose 
(MAD) study to evaluate the safety, tolerability, PK, immunogenicity, and PD of 
AMG 592 in subjects with SLE.  Subjects will be treated for a total of 12 weeks after 
which they will be followed for an additional 6 weeks for safety and additional PK/PD 
data collection. 
Approved  
  AMGEN~ 
Product :  AMG 592  
Protocol Number:  20170103  
Date:  25 June 2020  Page 11 of 97 
CONFIDENTIAL   Five dosing cohorts are planned for the study.  For cohorts 1,  2, and 3, subjects within a 
dosing-cohort will be randomized in a 5:2 ratio to AMG 592 (n = 5 ) or placebo (n = 2) as 
follows:  cohort 1 (  µg  cohort 2 (  µ g  and 
cohort 3 (  µg ]), in addition to standard of care therapy.  For 
cohorts 4 and 5, subjects within a dosing-cohort will be randomized in a 3:1 ratio to 
AMG 592 (n = 3) or placebo (n = 1) as follows:  cohort 4 (  µg  and cohort 
5 (  µg  in addition to standard of care therapy.  Dosing cohorts will enroll 
sequentially.  A Dose Level Review Meeting (DLRM) will convene after the last subject in 
each cohort completes the week 4 visit.  The decision to dose the next cohort will be 
based on the aggregated review of safety data.  After incidents of interest (including 
selected adverse events or intolerable PD  levels) are observed, a Bayesian logistic 
regression model (BLRM) will be implemented to model these events before each DLRM  
to aid dosing recommendations .  Dose Level Review Meeting members will be 
responsible for dosing recommendations , which may include escalation to the next 
planned dose or a new higher dose, escalation to an intermediate dose (a dose lower 
than the next planned dose), de-escalation to a lower dose; continuation, delay, or termination of dosing.  Additional dosing cohorts may be added and/or existing cohorts 
may be expanded based on emerging data.  Dose Level Review Meeting members may 
also consider available aggregated summaries of emerging PK and PD data.  Amgen DLRM members may consider safety, PK and PD data from other completed and 
ongoing phase 1b studies to aid dosing recommendations .  Emerging safety, PK , and 
PD data from ongoing AMG  592 studies may be used to support recommendations  to 
skip dosing cohorts, reduce dosing cohort size or change doses for a given cohort or stop the study entirely . 
Number of Subjects 
Within each cohort subjects will be randomized to AMG 592 or placebo in a 5:2 ratio 
(cohorts 1, 2, and 3) or in a 3:1 ratio (cohorts 4 and 5).  It is planned that approximately  
29 subjects will be randomized, with 21 subjects randomized to AMG 592, and 
8 subjects randomized to placebo.  The total sample size may exceed 29 subjects  and 
the number of subjects per cohort may exceed the planned cohort size if, following a 
DLRM recommendation or Amgen decision to evaluate additional doses  (or further 
evaluate currently planned doses) , dosing cohorts are added and/or existing cohorts are 
expanded, or subjects are replaced as per Section 5.2.1.  Additional subjects may be 
Approved  
  AMGEN~ 

Product :  AMG 592  
Protocol Number:  20170103  
Date:  25 June 2020  Page 12 of 97 
CONFIDENTIAL   enrolled in each cohort (following originally planned randomization ratio)  to enable all 
screened eligible subjects to participate in the study.  
Summary of Subject Eligibility Criteria 
Subjects must be adults with SLE according to the Systemic Lupus International 
Collaborating Clinics (SLICC criteria) or by at least 4 of the 11 criteria of the 1997 American College of Rheumatology (ACR) classification criteria for SLE, with a history of 
at least one of the following:  antinuclear antibody ≥ 1:80; or elevated anti -dsDNA 
antibodies.  Subjects must be on a SLE treatment for ≥  12 weeks, may be taking 
≤ 3 SLE treatments, and have a stable dose for ≥ 4 weeks prior to day 1.  Subjects 
must have a prednisone dose ≤ 20 mg daily (or other equivalent OCS) with stable dose 
≥ 2 weeks prior to day 1.  Subjects must be free of infections and significant concurrent 
medical conditions and laboratory abnormalities including a negative test for 
tuberculosis, hepatitis B and C, human immunodeficiency virus, and urine drug and 
alcohol.  Women of childbearing potential must have a negative pregnancy test at 
screening and baseline and must agree to use a highly effective method of birth control.  
For a full list of eligibility criteria, please refer to Section 6.1 to Section 6.2. 
Treat
ments 
AMG 592 and placebo will be manufactured and packaged by Amgen Inc. and 
distributed using Amgen clinical study drug distribution procedures.  Both are liquid formulations presented in highly similar glass vials and stored in the same manner.  AMG 592 or placebo will be administered by SC injection . 
Five dose cohorts are planned (cohort 1:   µg  cohort 2:   µg  
cohort 3 :   µg  cohort 4:   µ g  and cohort 5:   µg  
Procedures  
Written informed consent must be obtained from all subjects before any study -specific 
screening procedures are performed.  The following procedures will occur per the 
schedule of activities:  medical and medication history, physical examination, physical 
measures, vital signs, electrocardiograms, prior and concomitant medication 
assessment, tuberculosis testing, urinalysis, and blood draw for serum chemistry, 
hematology, hepatitis B and C testing, human immunodeficiency virus testing, PK/PD, anti-AMG 592 antibodies, biomarker development and pharmacogenetics sample.  
Women of childbearing potential will have pregnancy tests performed at screening and 
at regular interval s during the study.  Safety assessments including adverse events, 
Approved  
  AMGEN~ 

Product :  AMG 592  
Protocol Number:  20170103  
Date:  25 June 2020  Page 13 of 97 
CONFIDENTIAL   serious adverse events, and disease-related events, will be performed throughout the 
safety follow -up. 
For a full list of study procedures, including the timing of each procedure, please refer to 
Section 9.2 and the S chedule of Activities in Table 2-1  and Table 2-2 . 
Statistical Considerations 
Des
criptive statistics will be provided for selected demographics, safety, PK, PD, 
immunogenicity, and biomarker data.  Descriptive statistics on continuous 
measurements will include means, medians, Q1, Q3, standard deviations, and ranges, 
while categorical data will be summarized using frequency counts and percentages.  
Data will be presented and summarized by treatment and also by time as appropriate. 
Subject incidence of all treatment-emergent adverse events will be tabulated by system 
organ class and preferred term.  Subject incidence of fatal adverse events, serious 
adverse events, adverse events leading to withdrawal from investigational product or other protocol -required therapies, and significant treatment emergent adverse events will 
also be provided.  Subject incidence of disease-related events, and fatal disease-related 
events, if applicable, will be tabulated by system organ class and preferred term. 
The analyses of safety laboratory endpoints will include summary statistics at selected 
time points by treatment group.  Shifts in grades of safety laboratory values between the 
baseline and the worst on-study value will be tabulated.  
For a full description of statistical analysis methods, please refer to Section 10. 
C
lick or tap here to enter text.   Enter Sponsor Name  
Approved  
  AMGEN~ 
Product:  AMG 592  
Protocol Number:  20170103  
Date:   25 June 2020  Page 14 of 97 
CONFIDENTIAL   2. Study Schema and Schedule of Activities 
2.1 Study Schema  
Figure 2-1 .  Study Schema 
 
DLRM  = Dose Level Review  Meeting; . 
Each of cohort s 1, 2, and 3 will plan to enroll  5 AMG 592:  2 placebo subjects  and cohorts 4 and 5 will plan to enroll  3 AMG 592:  1 placebo subject .  Doses  and 
size of treatment cohorts may change as determined by  emerging safety  data, Bayesian logistic regression model (BLRM ), and pharmacokinetic/pharmacodynamic 
modeling.  
DLRM:  4 weeks after the last subject in cohort enrolled  
Treatment Period:  12 weeks   
Approved  
  AMG 592  µg  or Placebo 
~ --!-r-----.--t---------; Treatment 
Follow -up 
Week 12 Week 18 
~ ------------" '--i L-_T"A_ M_G-59_2 µ--:g: _o_r-:-P- l_ac_e_b_o __ -:---F-0_ 1 _ 1o_w_-_u_p_~ , 
Treatment 
Week 12 Week 18 
I 3 1------------------------------------------------------AMG 592  µg  or Placebo Follow-up 
Treatment 
Week 12 Week 18 
AMG 592  µg  or Placebo Follow-up 
Treatment _J 
Week 12 Week 18 
EE} ------------·- -------------------·--- AMG 592  µg  or Placebo Follow-up 
Treatment _J 
Week 12 Week 18 

Product:  AMG 592  
Protocol Number:  20170103  
Date:   25 June 2020  Page 15 of 97 
CONFIDENTIAL   2.2 Schedule of Activities 
Table 2-1 .  Schedule of Activities:  Screening and Treatment Period 
 Screening  (- 28) Day -1 Treatment Period  
Study week  1 2 3 4 5 6 7 8 9 10 11 12 
Study day 1m 2m 3m 4m 8 11m 15 22 29 36 43 50 57 64 71 78 85m 86m 87m 88m 
Hours post dose  Pre-
dose  0 0.25
-2.0 6 12 24 48 72             Pre-
dose  
(ET)k 0 0.25
-2.0 6 12 24 48 72 
GENERAL AND SAFETY ASSESSMENTS 
Informed consent  X                              
Eligibility  X X X                            
Demographics  X                              
Physical examination  X              X    X    X        
Height  X                              
Weight  X  X                    X        
Medical history  X X                             
Substance use  X X X     X X X X X X X X X X X X X X X X     X X X 
Strenuous Activity 
Assessment  X X             X    X    X        
ECGa X X               X           X   
Vital signs  X X X  X X X X X X X X X X X X X X X X X X X X X X X X X X 
Chest X -rayb X                              
Adverse eventsc     X X X X X X X X X X X X X X X X X X X   X X X X X 
Serious adverse eventsc X X X  X X X X X X X X X X X X X X X X X X X   X X X X X 
Disease -related eventsc     X X X X X X X X X X X X X X X X X X X   X X X X X 
Prior therapies review  X X X                            
Concomitant medication  
review      X X X X X X X X X X X X X X X X X X X     X X X 
Page 1 of 3  
Foot
notes are defined on the last page of the table   
Approved  
  AMGEN~ 
Product:  AMG 592  
Protocol Number:  20170103  
Date:   25 June 2020  Page 16 of 97 
CONFIDENTIAL   Table 2-1 .  Schedule of Activities:  Screening and Treatment Period 
 Screening  (-28)  Day -1 Treatment Period  
Study week  1 2 3 4 5 6 7 8 9 10 11 12 
Study day 1m 2m 3m 4m 8 11m 15 22 29 36 43 50 57 64 71 78 85m 86m 87m 88m 
Hours post dose  Pre-
dose  0 0.25
-2.0 6 12 24 48 72             Pre-
dose  
(ETk) 0 0.25
-2.0 6 12 24 48 72 
LABORATORY ASSESSMENTS  
Serum and/or urine 
pregnancy testd X X             X    X    X        
Tuberculosis teste X                              
Urine drug/alcohol screen  X                              
HIV, Hepatitis B and Cf X                              
C3 and C4 complementf  X         X    X    X    X        
Anti-dsDNA  X X         X    X    X    X        
Antinuclear antibodyl X X                             
Hematologyf X X      X     X  X  X  X  X  X        
Chemistryf X X             X    X    X        
FSHg X                              
Urinalysis   X             X    X    X        
PBMCf   X        X    X    X    X        
EFFICACY ASSESSMENTS  
SLEDAI -2K  X             X    X    X        
PHARMACODYNAMIC ASSESSMENTS 
Lymphocyte subsetsh   X     X  X X X X X X X X X X X X X X        
PHARMACOKINETICS AND ANTIBODIES  
Pharmacokinetic samplesh   X   X X X X X X X X X X X X X X X X X X   X X X X X 
Anti-AMG 592 antibodyf   X          X  X    X    X        
BIOMARKER AND PHARMACOGENETICS 
Biomarker development 
samplef   X     X  X X  X  X    X    X        
Pharmacogenetics samplei   X                            
Page 2 of 3  
Footnotes are defined on the next  page of the table   
Approved  
  AMGEN~ 
Product:  AMG 592  
Protocol Number:  20170103  
Date:   25 June 2020  Page 17 of 97 
CONFIDENTIAL   Table 2-1 .  Schedule of Activities:  Screening and Treatment Period 
 Screening  (-28)  Day -1 Treatment Period  
Study week  1 2 3 4 5 6 7 8 9 10 11 12 
Study day 1m 2m 3m 4m 8 11m 15 22 29 36 43 50 57 64 71 78 85m 86m 87m 88m 
Hours post dose  Pre-
dose  0 0.25
-2.0 6 12 24 48 72             Pre-
dose  
(ET)k 0 0.25
-2.0 6 12 24 48 72 
INVESTIGATIONAL PROD UCT ADMINISTRATION  
Investigational product QWj    X       X  X X X X X X X X X X  X       
Investigational product 
Q2Wj    X         X  X  X  X  X   X       
Page 3 of 3  
EC
G = electrocardiogram; ET = early termination; FSH = follicle stimulating hormone; HIV = human immunodeficiency virus; PBMC = peripheral blood mononuclear 
cell; PK = pharmacokinetics; QW = every week; Q2W = every other week; SLEDAI-2K  = Systemic Lupus Erythematosus Disease Activity Index  2000 . 
a single ECG will be collected at screening and after day -1.  At day -1 (baseline) a triplicate ECG will be collected.  See Section 9.2.3.3.  
b Only for subjects with a positive tuberculosis test (ie, positive purified protein derivative [PPD] or a positive or indeterminate Quantiferon)  
c For subjects who complete the study at week 18, the visit includes all required safety follow -up data collection (see  Table 2-2 ).  For subjects who terminate the study 
early (ie, prior to completing the week 18 visit), the safety follow -up visit 6 weeks (± 3 days) after the last dose of investigational product will be a visit to collect 
adverse events, serious adverse events, disease related events, ECG, hematology and concomitant medicat ions only. 
d For women of childbearing potential, serum pregnancy test is required at screening.  All other pregnancy tests are urine.  
e Either a PPD or Quantiferon test will be done during screening.  
f Blood samples must be collected prior to administration of investigational product  with the exception of the 6 and 12 hour PK samples on days 1 and 85.    
g Can be done as a part of the clinical chemistry  
h Pharmacokinetic  and lymphocyte subset blood samples should be collected at the exact nominal time point as noted above (see hour postdose column).  If unable to 
collect a blood  sample at the specified nominal time point, collect it as close as possible to the nominal time point and record the actual collection time.  For samples 
without exact nominal time point ( ie, days 8 to 78), PK samples must be collected prior to administration of investigational product, where appropriate.  
Pharmacokinetic  and lymphocyte subset samples not collected at exact nominal time point will not be considered protocol deviations.  
i DNA will be extracted only in subjects who provide additional consent for pharmacogenetics testing.  
j Investigational product must be administered within ± 12 hours from the scheduled time point up until week 4.  After week 4, investigational product must be 
administered within ± 1 day of the scheduled time point.  If that window is missed, that dose will not be administered, and the next dose will be administered at the 
next scheduled dosing date.  Subjects will remain at the site for at least 1 hour following the first and second doses of investigational product and for at least 
30 minutes following subsequent doses . 
k Subjects who withdraw from investigational product early will complete an early termination visit that includes the week 12 (predose)  assessments.   
l To be collected at screening but not required for eligibility unless subject has no documented prior history of antinuclear antibody  (ANA) ≥ 1:80 or elevated 
anti-dsDNA.  
m For description of home healthcare services available, see Section 9.2.3.4.   
Approved  
  AMGEN~ 
Product:  AMG 592  
Protocol Number:  20170103  
Date:   25 June 2020  Page 18 of 97 
CONFIDENTIAL   Table 2-2 .  Schedule of Activities Follow -up 
 
Follow -up 
Study week 13 14 16 18/SFU/EOSa 
Study day 92 99 113 127 
GENERAL AND SAFETY ASSESSMENTS  
Weight     X 
Vital signs  X X X X 
ECG     X 
Adverse events  X X X Xa 
Serious adverse events  X X X Xa 
Disease -related events  X X X Xa 
Concomitant medications  review  X X X Xa 
LABORATORY ASSESSMENTS  
Urine pregnancy test    X X 
Anti-dsDNA and C3 and C4 complement     X 
Hematology   X X X 
Chemistry     X 
PBMC     X 
PHARMACODYNAMIC ASSESSMENTS  
Lymphocyte subsets  X X X X 
PHARMACOKINETICS AND ANTIBODIES  
Pharmacokinetic samples  X X X X 
Anti-AMG 592 antibody     X 
BIOMARKER  
Biomarker development sample     X 
ECG = electrocardiogram;  EOS = end of study for individual subject; PBMC = peripheral blood mononuclear cell ; SFU = Safety follow -up  
a For subjects who complete the study at week 18, the visit includes all required safety follow up data collection.  For subjects who terminate the study early (ie, prior to 
completing the week 18 visit), the safety follow -up visit 6 weeks (± 3 days) after the last dose of investigational product will be a visit to collect  adverse events, serious 
adverse events, disease related events, ECG , hematology,  and concomitant medications only  
  
Approved  
  AMGEN~ 
Product:  AMG 592  
Protocol Number:  20170103  
Date:  25 June 2020  Page 19 of 97 
CONFIDENTIAL   3. Introduction 
3.1 Study Rationale 
This phase 1b study is a double-blind, placebo controlled, multiple ascending dose 
(MAD) study to evaluate the safety and tolerability of AMG 592 in subjects with systemic  
lupus erythematosus (SLE) and to determine the recommended phase 2 dose(s). 
3.2 Background 
3.2.1 Disease 
Systemic lupus erythematosus  is a multisystem autoimmune disease of unknown cause 
with diverse clinical manifestations that disproportionately affects minorities (eg, in the 
United States, blacks and Hispanics) and women of childbearing potential 
(Rhaman and Isenberg, 2008; Kotzin, 1996).  In the U nited States (US), moderate to 
severe SLE is estimated to affect one-third of the more than the 250  000 patients 
diagnosed with lupus.  The progression of Systemic Lupus Erythematosus (SLE) may 
vary from mil d episodes to severe, even fatal outcomes with symptoms varying widely in 
individuals over time and characterized by periods of remission and flare.  Systemic lupus erythematosus  can affect the skin (rash), musculoskeletal system (arthritis, bone 
tissue death), nervous system (seizures, psychosis), lungs (pleuritis, pneumonitis), and 
the blood (venous or arterial clots, anemia).  In addition, approximately 65% of patients 
will develop lupus nephritis, which is an inflammation of the kidney that can range fr om 
mild glomerulonephritis to severe diffuse proliferative glomerulonephritis (Adams  et al, 2006).   
Currently, corticosteroids, immunosuppressants, and cytotoxic agents are frequently used to control active disease, but significant need exists for more effective therapies 
with fewer short- and long-term toxicities.  Although the clinical heterogeneity of SLE 
presents challenges in the diagnosis, antibodies to nuclear components represent 
almost a prerequisite for the disease.  The presence of class -switched 
immunoglobulin G (IgG) autoantibodies implicate immune dysregulation as a driving 
force for disease pathogenesis, with T cells appearing to play a role in the development 
of autoantibody production by B cells. 
3.2.1.1 Interleukin 2 and T R egulatory Cells in Systemic Lupus 
Erythematous 
T regulatory cells (Tregs) are a subset of T cells that maintain self- tolerance by 
suppressing the activation and expansion of autoreactive lymphocytes.  Defects in Treg 
numbers or function have been described in SLE patients and are thought to contribute 
Approved  
  AMGEN~ 
Product:  AMG 592  
Protocol Number:  20170103  
Date:  25 June 2020  Page 20 of 97 
CONFIDENTIAL   to SLE pathogenesis ( Zhang et al, 2008; Bonell y et al, 2009; Myara et al , 2005; 
Suen et al 2008; von Spee-Mayer et al 2015).  Interleukin-2 (IL-2), a multi -functional 
cytokine produced predominantly by activated cluster of differentiation 4+ (CD4+ ) 
T cells, is a key growth factor for Tregs and is essential for Treg maintenance, survival 
and metabolism ( Malek  and Castro, 2010; Boyman and Sprent, 2012).  Impaired IL-2 
production has been reported in patients with SLE ( Linker-Israeli et al, 1983;  
Alcocer-Varela and Alarcon Segovia, 1982; von Spee-Mayer et al, 2015).  Moreover , 
reduced levels of circulating IL-2 have been associated with Treg dysfunction in SLE 
patients (Lieberman and Tsokos , 2010; von Spee-Mayer et al, 2015).  These data 
suggest that immune homeostasis in SLE patients m ay be restored by correction of Treg 
dysfunction and numerical deficiency through treatment with low dose IL-2.  
3.2.1.2 Low Dose Interleukin 2 in Inflammatory Disease 
Low dose IL-2 (aldesleukin) has been shown to increase Treg numbers in multiple 
inflammatory diseases such as Type 1 Diabetes ( Yu et al, 2015), chronic graft versus 
host disease (GVHD)  (Koreth et al, 2011), hepatitis c virus induced vasculitis 
(Sadoun et al, 2011) and alopecia areata (Castela et al, 2014); as well as to correct 
defects in Treg function in SLE ( von Spee-Mayer  et al, 2015), Type 1 Diabetes 
(Long et al, 2010;  Long et al, 2012)  and GVHD ( Matsuoka et al, 2013).  Genetic variants 
of the IL 2 receptor have been associated with the severity of rheumatoid arthritis ( RA) 
joint destruction and persistence ( van Steenbergen et al, 2015). 
The therapeutic efficacy of low dose IL-2 has also been studied in chronic GVHD 
(cGVHD) ( Koreth et al, 2011; Koreth et al, 2016), hepatitis C induced vasculitis 
(Sadoun et al, 2011), and alopecia areata ( Castela et al, 2014).  The clinical response to 
low dose IL- 2 has been promising in these small early phase studies in multiple diverse 
inflammatory conditions , with efficacy reported in all indications.  In all of these 
conditions the overall safety and tolerability profile of low -dose IL-2 has been acceptable 
with mild to moderate constitutional symptoms associated with higher levels of exposure.  
However, the therapeutic window between adequate Treg enrichment and stimulation of 
effector cells is narrow and may limit achievement of optimal Treg expansion.  For instance, in a recent phase 1b clinical trial of cGVHD (ClinicalTrials.gov 
[STUDY_ID_REMOVED]), aldesleukin, a human recombinant IL-2, given at the dose of 
3 x 10
6 IU/m2 daily induced persistent National Cancer Institute Common Terminology 
Criteria for Adverse Events (CTCAE) grade 1 constitutional symptoms (fever, malaise, and arthralgia) necessitating a 50% dose reduction (Koreth et al, 2011).  In addition, 
Approved  
  AMGEN~ 
Product:  AMG 592  
Protocol Number:  20170103  
Date:  25 June 2020  Page 21 of 97 
CONFIDENTIAL   aldesleukin can activate pro-inflammatory/effector lymphocytes such as CD4+ T effector 
cells (Teff) and natural killer (NK) cells, which may compromise efficacy and safety.  
These data suggest the potential for a therapeutic agent with greater Treg selectivity and 
a prolonged PD effect compared with recombinant IL-2. 
3.2.1.3 Clinical Experience With Low D ose IL-2 in Systemic Lupus 
Erythematosus 
Treatment with low dose IL-2 has been associated with clinical efficacy in 2 small clinical 
trials.  In one recently reported study of 12 patients with moderate to severe 
SLE (Systemic Lupus Erythematosus Disease Activity Index [SLEDAI] score ≥  6 despite 
treatment with 2 different immunosuppressive therapies), 10/12 subjects (83.3%) achieved a reduction in SELENA SLEDAI score and 8/12 (66.7%) achieved a clinical response after receiving four 5-day cycles of low dose IL-2 therapy  separated by 
washout periods of 9 and 16 days .  Clinical responses included complete resolution of 
SLE manifestations including rash, arthralgias, myositis  and al opecia.  Complement 
levels increased but no change in anti -double stranded DNA (anti -dsDNA) antibodies 
was observed.  R egulatory T cells  numbers increased in all treated subjects 
(Humrich  et al, 2016; Humrich  et al, 2015).  In a second study of 38 SLE patients who 
completed three 2-week cycles of low dose IL-2 over 12 weeks, 34/38 subjects (89.5%) achieved a Systemic Lupus Erythematosus Responder Index 4 ( SRI-4) response at the 
end of 12 weeks, with concomitant decreases in anti -dsDNA antibodies and increase in 
complement levels .  Regulatory T cells  numbers increased in most treated subjects 
(He et al, 2016).  In both studies low dose IL-2 was generally well - tolerated, though 
constitutional symptom s (eg, fever, myalgias, arthralgias, flu -like symptoms ) were 
reported at the higher dose levels.  Overall these studies provide compelling support for 
further investigation of low dose IL-2 for the treatment of SLE.  
3.2.2 Amgen Investigational Product Background:  AMG 592 
AMG 592 is an Fc IL-2 mutein fusion protein with increased Treg selectivity  compared to 
recombinant IL-2, which has been developed to preferentially expand Tregs in subjects 
with inflammatory diseases (refer to the Investigator’s Brochure for mor e details).  
Interleukin-2 is a key growth factor for Tregs and is essential for Treg development, 
homeostasis and function.  At low doses IL-2 binds preferentially to the α -subunit (CD25) 
of the high-affinity IL-2 receptor which is expressed constitutively by Tregs and is absent 
on naive T-cells and unactivated T memory cells.  This results in selective activation of 
Tregs.  However, at higher doses IL- 2 also activates other immune cells  such as CD4+ 
and CD8+ Teff, NK  cells and natural killer T cells (NKT) cells via the dimeric low affinity 
Approved  
  AMGEN~ 
Product:  AMG 592  
Protocol Number:  20170103  
Date:  25 June 2020  Page 22 of 97 
CONFIDENTIAL   IL-2 receptor.  Compared with aldesleukin, AMG 592 exhibits greatly improved selectivity 
for Tregs over Teff and NK cells both in vitro and in vivo, potentially resulting in an improved therapeutic margin.  In addition, the Fc domain of AMG 592 provides a 
prolonged half-life compared with aldesleukin, thus reducing dosing frequency to maintain Treg enrichment. 
3.2.2.1 Toxicolog y 
3.2.2.2 Human Exposure 
Approved  
  AMGEN~ 

Product:  AMG 592  
Protocol Number:  20170103  
Date:  25 June 2020  Page 23 of 97 
CONFIDENTIAL   A detailed description of the chemistry, pharmacology, efficacy, and safety  of AMG 592 
is provided in the Investigator’s Brochure. 
3.3
 Risk A ssessment  
Repeated SC doses of up to  μg administered  and  have been studied for 
up to 12 weeks in subjects with rheumatoid arthritis and SLE.  In addition, repeated SC 
doses of up to  µg  for up to 52 weeks have been studied in subjects with 
cGVHD.  The most frequent adverse event was  mild (grade 1 or 2) painless erythema 
at or near the injection site, sometimes accompanied by pruritus, that was self -resolving.  
Two serious hypersensitivity reactions to AMG 592 have been reported, though none 
occurred in the current study .  No clinically significant therapeutic related abnormalities 
in electrocardiograms  (ECGs), hematological or biochemical laboratory investigations, or 
vital signs have been reported.  No adverse events greater than grade 2 assessed as 
related to AMG 592 nor any deaths have occurred in the phase 1b part of the current study in SLE patients.  More detailed information about the known and expected risks 
Approved  
  AMGEN~ 

Product:  AMG 592  
Protocol Number:  20170103  
Date:  25 June 2020  Page 24 of 97 
CONFIDENTIAL   and reasonably expected adverse events associated with AMG 592 may be found in the 
Investigator’s  Brochure. 
4. Objectives, Endpoints and Hypotheses 
4.1 Objectives and Endpoints 
 
Objectives Endpoints 
Primary  
• To evaluate the safety and tolerability 
of
 subcutaneous (SC) dose 
administrations of AMG  592 in subjects 
with systemic lupus erythematosus 
(SLE)  • Treatment -emergent adverse events  
• Clinically significant changes in physical  
examinations, vital signs, and laboratory safety tests  
Secondary 
• To characterize the pharmacokinetic 
(
PK) profile following treatment with 
AMG  592 • AMG 592 serum concentration and PK 
parameters including, but not limited to, 
maximum observed concentration (C max), the 
time of maximum observed concentration (T
max), and area under the concentration -time 
curve over a dosing interval (AUC tau) after 
the first and last doses  
• To evaluate anti -AM G 592 antibody 
formation  • Incidence of anti -AMG  592 antibodies  
• Cross -reactivity of anti -AMG  592 antibodies 
with human interleukin -2 (IL-2) 
• Incidence of anti -AMG 592 and anti -IL 2 
neutralizing antibodies  
Exploratory  
• To explore the effect of 
t
reatment with AMG 592 on 
measures of inflammation at various tim e points  • Change from baseline in anti -double 
stranded DNA (anti -dsDNA), and C3 
and C4 complements at all time points collected  
• To explore the effect of 
t
reatment with AMG 592 on 
measures of disease activity at various time points  • SLEDAI -2K score and change from 
baseline at all time points collected  
• To evaluate the immunological 
ef
fects of AMG 592  • Fold changes from baseline of Treg, 
Tcon, and NK absolute cell counts 
(cells/µL) after AMG  592 
a
dministration 
• Changes in Treg/Tcon ratio after AMG  592 admin istration   
  
4.2 Hypotheses 
AMG 592 will be safe and well tolerated in subjects with SLE. 
Approved  
  AMGEN~ 
Product:  AMG 592  
Protocol Number:  20170103  
Date:  25 June 2020  Page 25 of 97 
CONFIDENTIAL   5. Study Design 
5.1 Overall Design 
This phase 1b study is a double-blind, placebo- controlled, multiple ascending 
dose (MAD ) study to evaluate the safety, tolerability, PK, immunogenicity , and PD of 
AMG 592 in subjects with SLE.  Subjects within a dosing cohort will be randomized to 
AMG 592 or placebo in a 5:2 ratio (cohorts 1, 2, and, 3) or in a 3:1 ratio (cohorts 4 and 5) 
in addition to standard of care therapy as shown in  AMG 592 or placebo will 
be administered either  by SC injection.  Dosing cohorts will enroll 
sequentially.  
The decision to dose-escalate will be based on the blinded review of safety data during 
the dose lev
el review meeting(s) (DLRM ).  The DLRM team will include representatives 
from Amgen’s AMG 592 Early Development Team (Amgen Medical Monitor, Amgen 
Global Safety Officer, Clinical Study Manager, and other team members, as appropriate) 
and the site investigator(s).  The DLRM members will be responsible for dosing 
recommendations , which may include escalation to the next planned dose or a new 
higher dose, escalation to an intermediate dose (a dose lower than the next planned 
dose), de-escalation to a lower dose; continuation, delay, or termination of dosing.  For 
further details on the DLRM see Appendix 3.  
After the last subject enrolled in each cohort completes the week 4 visit, a DLRM will 
convene to determine the acceptability of dose escalation.  The recommendation to dose 
the next cohort will be based on the aggregated review of safety data as well as other 
information as described below.  After incidents of interest (including selected adverse 
events or intolerable PD levels) are observed, a Bayesian logistic regression 
model  (BLRM) (Bailey et al, 2009; Neuenschwander et al, 2008) will be implemented to 
model these events before each DLRM  to aid dosing decisions.  Dose  level review 
meeting members may also consider available aggregated summaries of emerging PK 
Approved  
  AMGEN~ 

Product:  AMG 592  
Protocol Number:  20170103  
Date:  25 June 2020  Page 26 of 97 
CONFIDENTIAL   and PD data.  Amgen DLRM members may consider  safety, PK  and PD data from other 
completed and ongoing phase 1b studies to aid dosing recommendations  including 
skipping dosing cohorts, reduc ing dosing cohort size or changing doses for a given 
cohort or stopping the phase 1b portion of the study entirely.  If emerging data from other 
studies is used in support of dosing recommendations , a dose will only be declared 
tolerable if it is supported by safety from at least 5 subjects at or above this dose level 
across all phase 1b studies.   
Additional dosing cohorts may be added and/or existing cohorts may be expanded.  
These cohorts may be used to explore alternate dosing levels and/or dosing schedules or add additional subjects at previously given dose levels.  A DLRM is required for escalation to higher doses but not for allocation of additional subjects to doses equivalent to or lower than previously given that have been deemed tolerable.   
Subjects will be treated for a total of 12 weeks after which they will complete a 6-week 
follow -up period until week 18 for collection of additional safety, PK and PD data as 
described in the Schedule of Activities ( Table 2-2 ).  In the event that a subject terminates 
the study early (ie, prior to week 18), a safety follow-up visit will be completed 
(6 weeks  [± 3 days ]) after the last dose of investigational product for collection of 
adverse events, serious adverse events, disease related events , ECG, hematology and 
concomitant medications  only. 
Home Healthcare Services 
The investigator may utilize  a qual i
 fied home healthcare service provider  approved by 
the sponsor to conduct the procedures  (described in Section 9.2.3.4) required during 
study visits, subject to the investigator’s direction.  Home healthcare services will not be 
used for investigational product administration.   Home healthcare staff must be included 
on the study delegation log (authorized by the investigator) before any study -related 
tasks to be conducted by each home healthcare provider are started.  
In addition, study -specific training including requirements for recording source 
documentation for the home healthcare provider , must be completed before they 
conduct any study -related tasks.  
If ordered by the principal investigator  (PI) or authorized physician, the subject will be 
visited by a qualified home  healthcare service provider at designated study visits  as 
specified in Section 9.2.3.4.  
Approved  
  AMGEN~ 
Product:  AMG 592  
Protocol Number:  20170103  
Date:  25 June 2020  Page 27 of 97 
CONFIDENTIAL   Following home healthcare visit, this information will be documented on the home health 
care services visit worksheet and forwarded to the investigator. 
A comprehensive list of all home healthcare services, as well as mandatory procedural 
and data collection requirements, will be separately provided in a home health care 
manual.  
The overall study design is described by a study s chema in Section 2.1.  The endpoints 
are defined in Section 4.1. 
5.2
 Num ber of Subjects 
Subjects will be randomized to receive AM G 592 or placebo in a 5:2 ratio (cohorts 1, 2, 
and 3) or in a 3:1 rati o (cohorts 4 and 5) .  Sufficient subjects will be randomized to yield 
approximately 29 subj ects (approximately 21 randomized to AMG 592 and 8 randomized 
to placebo; see Sec tion 5.2.1).  The total sample size may exceed 29 subjects  and the 
number of subjects per cohort may exceed the planned cohort size if, following a DLRM 
recommendation or Amgen decision to evaluate additi onal doses  or further evaluate 
currently planned doses, dosing cohorts are added and/or existing cohorts are 
expanded, or if subjects are replaced as per Section 5.2.1 .  Additional subjects  may be 
enrolled in each cohort (following originally planned randomization ratio)  to enable all 
screened eligible subjects to participate in the study.  
Subjects in this clinical investigation shall be referred to as “subjects .”  For the sample 
size justification, see Section 10.1.  
5.2.1 Replacem ent of Subjects 
Subjects who have been randomized but discontinue investigational medicinal product 
before completing the week  4 visit may be replaced. 
5.2.2 Number of Sites 
Approximately 20 si tes in North America and Europe will participate in the study.  Sites 
that do not enroll subjects within 3 months  of s ite initiation may be closed. 
5.3 End of  Study 
5.3.1 End of Study Definition 
Primary Completion:   The pr imary completion date is defined as the date when the 
last subject is assessed or receives an intervention for the final collection of data for the 
pr
imary endpoint(s), whether the study concluded as planned in the protocol or was 
terminated early. 
Approved  
  AMGEN~ 
Product:  AMG 592  
Protocol Number:  20170103  
Date:  25 June 2020  Page 28 of 97 
CONFIDENTIAL   If the study concludes prior to the primary completion date originally planned in the 
protocol (ie, early termination of the study), then the primary completion will be the date when the last subject is  ass
 essed or receives an intervention for evaluation in the study 
(ie, last subject last visit). 
End of Study:  The en d of s tudy date is defined as the date when the last subject 
across all sites is  assessed or receives an intervention for evaluation in the study (ie, last 
subject last visit), following any additional parts in the study (eg, safety follow -up) , as 
applicable. 5.3.2 St
 udy Duration for Subjects 
The study will consist of up to a 28-day s creening period, a 12 -week treatment period 
and a 6-week follow up.  The maximum duration of trial participation for an individual 
subject will be 22 weeks.   
5.4 Justification for Investigational Product Dose 
Approved  
  AMGEN~ 

Product:  AMG 592  
Protocol Number:  20170103  
Date:  25 June 2020  Page 29 of 97 
CONFIDENTIAL   5.5 Patient Input on Study Design 
Patient input was not obtained for design of this study. 
6. Study Population 
Investigators will be expected to maintain a screening log of all potential study 
candidates that inc ludes limited information about the potential candidate (eg, date of 
screening).  This  log will  be completed and updated via an Interactive R esponse 
Technology  (IRT). 
Eligibility criteria will be ev aluated during screening and day -1.  
Before any  study- specific activities/procedures, the appropriate written informed consent 
must be obtained (see Appendix 3). 
Prospective approv al of protocol deviations to recruitment and enrollment criteria, also 
known as protocol waivers or exemptions  wi ll not be provided. 
6.1 Inclusion C r iteria  
Subjects  are  eligible to be included in the study only if all of the following criteria apply:  
101 Subject has  pr ovided informed consent prior to initiation of any study-specific 
activities/procedures . 
102 Age ≥  18 years  to ≤ 70 years at screening. 
103 Fulfil ls diagnostic criteria for SLE according to the Systemic Lupus International 
Collaborating Clinics (SLICC) criteria or by at least 4 of the 11 criteria of  the 1997 
American College of Rheumatology (ACR)  classification criteria for SLE, with a 
history of at least one of the following : 
• Antinuclear antibody  ≥ 1:80; or 
• Elevated anti -dsDNA antibodies  
104 Removed 
105
 Removed 
106
 Removed 
107 May be taking ≤ 3 systemic SLE treatments  and the dose must be stable for 
≥ 4 weeks prior to day 1. 
Approved  
  AMGEN~ 

Product:  AMG 592  
Protocol Number:  20170103  
Date:  25 June 2020  Page 30 of 97 
CONFIDENTIAL   108 Prednisone dose ≤ 20 mg daily (or other equivalent oral corticosteroid) with 
stable dose ≥ 2 weeks prior to day  1 
109 Normal or clinically acceptable ECG values (12-lead reporting ventricular rate 
and PR, QRS, QT and QTc interval) at screening and baseline based on opinion of 
the investigator. 
110 Immunizations (tetanus, diphtheria, pertussis [Td/Tdap]) , seasonal influenza 
(during flu season), and pneumococcal (polysaccharide) vaccinations] up to date per local standards as determined by the investigator . 
6.2 Exclusion Criteria  
Subjects are
  excluded from the study if any  of the following criteria apply. 
Disease Related 
201 H
istory of lupus nephritis requiring induction therapy and/or lupus cerebritis  ≤ 1 
year prior to screening. 
202 Removed 
Other Medical Conditions 
203 Diagnosis of inflammatory joint or skin disease other than SLE  which would 
interfere with SLE disease assessment based on investigator judgement. 
204 Diagnosis of fibromyalgia which would interfere with SLE assessment according 
to the investigator . 
205 Prosthetic joint infection within 3 years of screening or native joint infection within 
1 year prior to screening. 
206 Active infection (including chronic or localized infections) for which anti -infectives 
were indicated within 4 weeks prior to day 1 OR presence of serious infection, 
defined as requiring hospitalization or intravenous anti -infectives within 8 weeks prior 
to day  1. 
207 Known history of active tuberculosis  
208 Positive test for tuberculosis during screening defined as either : 
• positive purified protein derivative (PPD) ( ≥ 5 mm of induration at 
48 to 72 hours after test is placed) OR positive Quantiferon test 
o a positive PPD and a history of Bacillus Calmette-Guérin vaccination 
are allowed with a negative Quantiferon test and negative chest X-ray. 
o a positive PPD test (without a history of Bacillus Calmette-Guérin 
vaccination) or a positive or indeterminate Quantiferon test are 
allowed if they have ALL of the following at screening: 
− no symptoms per tuberculosis worksheet provided by Amgen  
− documented history of a completed course of adequate 
prophylaxis (completed treatment for latent tuberculosis per local 
standard of care prior to the start of investigational product) 
Approved  
  AMGEN~ 
Product:  AMG 592  
Protocol Number:  20170103  
Date:  25 June 2020  Page 31 of 97 
CONFIDENTIAL   − no known exposure to a case of active tuberculosis after most 
recent prophylaxis  
− negative chest X -ray. 
209 Positive for hepatitis B surface antigen, hepatitis B core antibody (confirmed by 
hepatitis B DNA polymerase chain reaction [PCR] test) or detectable hepatitis  C virus 
RNA by PCR (screening is generally done by hepatitis C antibody [HepCAb], 
followed by hepatitis C virus RNA by PCR if HepCAb is positive).  A history of 
hepatitis B vaccination without history of hepatitis B is allowed. 
210 Positive for Human Immunodeficiency Virus (HIV) at screening, or known to be 
HIV positiv e. 
Approved  
  AMGEN~ 
Product:  AMG 592  
Protocol Number:  20170103  
Date:  25 June 2020  Page 32 of 97 
CONFIDENTIAL   211 Presence of one or more significant concurrent medical conditions per 
investigator judgment, including but not limited to the following: 
• poorly controlled diabetes or hypertension 
• chronic kidney disease stage IIIb, IV, or V  
• symptomatic heart failure (New York Heart Association class II, III, or IV ) 
• myocardial infarction or unstable angina pectoris within the past 12 months 
prior to randomization 
• severe chronic pulmonary disease (eg, requiring oxygen therapy ) 
• multiple sclerosis or any other demyelinating disease  
• major chronic inflammatory disease or connective tissue disease other than 
SLE (eg, RA ). 
212 Malignancy except non-melanoma skin cancers, cervical , or breast ductal 
carcinoma in situ within 5 years  of screening. 
213 Subjects with a urine test positive for illicit drugs or alcohol at the screening visit.  
Prescription medications detected by the drug test are allowed if they are being 
taken under the direction of a physician. 
214 History of alcohol or substance abuse within 6 months of screening. 
215 Current smoker, and/or use of any nicotine or tobacco containing products within 
the last 6 months prior to day 1.  These types of products include but are not limited to:  snuff, chewing tobacco, cigars, cigarettes, e lectronic  cigarettes, pipes, or  nicotine 
patches . 
216 Subject unwilling to limit alcohol consumption to ≤ 1 drink of alcohol per day and 
≤ 3 drinks per week for the duration of the study, where a drink is equivalent to 
12 ounces of regular beer, 8 to 9 ounces of malt liquor, 5 ounces of wine, or 
1.5 ounces of 80 proof distilled spirits. 
Prior/Concomitant Therapy  
217 Currently receiving or had treatment with:  cyclophosphamide, chlorambucil, 
nitrogen mustard, or a ny other alkylating agent ≤ 6 months prior to day  1 OR oral 
calcineurin inhibitors (eg, cyclosporine, tacrolimus, and sirolimus ) ≤ 4 weeks prior to 
day 1. 
218 Current or previous treatment for SLE with a biologic agent as follows:  
rituximab < 6 months prior to day 1, belimumab < 3 months prior to day 1, 
abatacept < 8 weeks prior to day 1. 
219 Currently receiving or had treatment with T cell depleting agents 
(eg, antithymocyte globulin, Campath)  or recombinant IL-2 (eg, Proleukin). 
220 Subjects who have received intra-articular or systemic corticosteroid injections 
within 4 weeks prior to day 1  or topical steroids within 2 weeks prior to day 1. 
Approved  
  AMGEN~ 
Product:  AMG 592  
Protocol Number:  20170103  
Date:  25 June 2020  Page 33 of 97 
CONFIDENTIAL   221 Administration of herbal supplements, vitamins, or nutritional supplements within 
30 days prior to the first dose of investigational product, and continuing use, if 
applicable, will be reviewed by the Investigator and the Amgen Medical Monitor to 
determine acceptability.  Written documentation of this review and Amgen 
acknowledgment is required for subject participation. 
Prior/Concurrent Clinical Study Experience 
222 Currently  r eceiving treatment in another investigational device or drug study, or 
less than 30  days at day  1 since ending treatment on another investigational device 
or drug study(ies).  Other investigational procedures while participating in this study 
are excluded. 
223 Subject previously enrolled in this study m ay not be re-enrolled unless  they fulfill 
the following criteria:  
• Have completed the study previously without any adverse events  deemed 
related to study drug. 
• Have received the last dose of AMG 592/placebo  > 6 months prior to the 
screening visit. 
• Must not have tested positive for neutralizing antibodies against AMG 592 at 
any time. 
Diagnostic Assessments 
224 Presence of laboratory abnormalities at screening including the following:  
• Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 1.5 x 
upper limit of normal (ULN). 
• Serum total bilirubin (TBL) ≥  1.5 mg/dL (≥  26 µmol/L) 
• Hemoglobin < 9.0 g/dL ( < 90 g/L) 
• Platelet count < 100,000/mm3 (100 x 109/L) 
• White blood cell count < 2,000 cells/mm3 (2.0 x 109/L) 
• Absolute neutrophil count (ANC) < 1,0 00/mm3 (1.0 x 109/L) 
• Calculated glomerular filtration rate of ≤  50 mL/min/1.73 m2 using the 
Modification of Diet in Renal Disease (MDRD) formula. 
225 Any other laboratory abnormality, which, in the opinion of the investigator, poses 
a safety risk, will prevent the subject from completing the study, will interfere with the 
interpretation of the study results, or might cause the study to be detrimental to the 
subject. 
Other Exclusions 
226 Female subject is pregnant or breastfeeding or planning to become pregnant or 
breastfeed during treatment and for an additional 6 weeks  after the last dose of 
investigational product.  
227 Females  of child-bearing potential with a positive pregnancy test (assessed by a 
serum pregnancy test at screening and a urine pregnancy test at baseline). 
Approved  
  AMGEN~ 
Product:  AMG 592  
Protocol Number:  20170103  
Date:  25 June 2020  Page 34 of 97 
CONFIDENTIAL   228 Female subjects of childbearing potential unwilling to use 1 highly effective 
method of contraception during treatment and for an additional 6 weeks after the last 
dose of investigational product.   Refer to Appendix 5 for additional contraceptive 
information. 
229 Subject has known sensitivity to any of the products or components to be 
administered during dosing. 
230 Subject likely to not be available to complete all protocol -required study visits or 
procedures, and/or to comply with all required study procedures (eg, Clinical Outcome Assessments ) to the best of the subject and investigator’s knowledge. 
231 History  or evidence of any other clinically significant disorder, condition or 
disease (with the exception of those outlined above) that, in the opinion of the investigator or Amgen physician, if consulted, would pose a risk to subject safety or 
interfere with the study evaluation, procedures or completion. 
6.3 Lifestyle Restrictions 
6.3.1 Alcohol and Tobacco 
At screening and throughout the duration of the study , subjects should not consume 
> 1 drink of alcohol per day and no more than 3 drinks per week , where a drink  is 
equivalent to 12 ounces of regular beer, 8 to 9 ounces of malt liquor, 5 ounces of wine, 
or 1.5 ounces of 80 proof distilled spirits . 
Subjects must abstain from alcohol consumption within 48 hours prior to each visit 
(including screening). 
Subjects must not use any nicotine or tobacco containing products throughout the study.  
These types of products include but are not limited to:  snuff, chewing tobacco, cigars, 
cigarettes, pipes, electronic cigarettes, or nicotine patches . 
6.3.2 Activity  
Subjects will abstain from strenuous exercise (eg, running, weight lifting for greater than 
1 hour) for 72 hours before each blood collection for clinical laboratory tests.   
6.4 Subject Enrollment  
Before subjects begin participation in any study- spec
 ific activities/procedures, Amgen 
requires a copy of the site’s written institutional review board/independent ethics 
committee (IRB/IEC) approval of the protocol, informed consent form, and all other 
subject information, if applicable (see A ppendix 3). 
The subject mus t personally sign and date the IRB/IEC and Amgen approved informed 
consent before commencement of study-specific procedures.  
Approved  
  AMGEN~ 
Product:  AMG 592  
Protocol Number:  20170103  
Date:  25 June 2020  Page 35 of 97 
CONFIDENTIAL   A subject is considered enrolled when the investigator decides that the subject has met 
all eligibility criteria.  The investigator is to document this decision and date, in the subject’s medical record and in/on the enrollment case report form (CRF).  
Each subject who enters into the screening period for the study (defined as the point at which the subject signs the informed consent form)  rec
 eives a unique subject 
identification number before any study -r elated activities/procedures are performed.  The 
subject identification number will be assigned by I RT.  This number will be used to 
identify the subject throughout the clinical study and must be used on all study documentation related to that subject.  
The subject identification number must remain constant throughout the entire clinical 
study; it must not be changed after initial assignment, including if a subject is rescreened.  This number will not necessarily be the same as the randomization number 
assigned for the study . 
  In the case of a subject re-enrolling to a new cohort, a new 
subject identification number will be assigned.  
6.5 Scr een Failures 
Screen failures are defined as subjects who consent to participate in the clinical study 
but are not subsequently enrolled in the study.  A minimal set of screen failure information will be collected that includes demography, screen failure details, eligibility 
criteria, medical history, prior therapies, and any serious adverse events. 
Individuals who do not meet the criteria for participation in this study (screen failure) may  
be rescreened (Section 9.1.1). 7. Treat
 ments 
Study treatment is defined as any investigational product(s), non-investigational 
product(s), placebo, or medical device(s) intended to be administered to a study subject 
according to the study protocol.  
Note that in several countries, investigational product and non-investigational product 
are referred to as investigational medicinal product and non- inv estigational medicinal 
product, respectively. 
The Investigational Product Instruction Manual (IPIM), a document external to this 
protocol, contains detailed information regarding the storage, preparation, destruction, 
and administration of each treatment shown in Sec tion 7.1 below. 
Approved  
  AMGEN~ 
Product:  AMG 592  
Protocol Number:  20170103  
Date:  25 June 2020  Page 36 of 97 
CONFIDENTIAL   7.1 Treatment Procedures  
7.1.1 Investigational Products 
7.1.1.1 Amgen Investigational Product:  AMG 592  
AMG 592 and placebo will be manufactured and packaged by Amgen Inc. and 
distributed using Amgen clinical study drug distribution procedures . 
Both are liquid formulations presented in highly similar glass vials  and stored in the 
same manner.  An IPIM containing detailed information regarding the storage, 
preparation, and administration of investigational product will be provided separately . 
7.1.1.1.1 Dosage Administration and Schedule 
AMG 592 or placebo will be administered by SC  injection  starting on Day 1.  
The following dose cohorts are planned: 
• Cohort 1:   µg  or placebo  
• Cohort 2:   µg  or placebo 
• Cohort 3:   µg  or placebo  
• Cohort 4:   µ g  or placebo 
• Cohort 5:   µ g  or placebo 
Investigational product will be administered by SC injection in the abdomen, thigh or 
upper arm by authorized site personnel.  A physician must be available at the time of 
investigational product administration.  
The dose of investigational product must be given within ± 12 hours of the specified time  
point up until week 4 (see Schedule of Activities , Table 2-1 ).  After week 4, doses of 
investigational product must be given within ± 1 day of the scheduled time point 
(see Schedule of Activities , Table 2-1 ).  If that window is missed, that dose will not be 
administered, and the next dose will be administered at the next scheduled dosing date. 
Subjects will remain at the site for at least 1 hour following the first and second doses of 
investigational product and for at least 30 minutes following subsequent doses. 
The amount of investigational product used in preparation, total volume of preparation, 
quantity administered, start date, start time, and box  number of AMG 592/placebo are to 
be recorded on each subject’s CRF. 
7.1.2 Non-investigational Products 
There are no therapies designated as non-investigational products in the study. 
Approved  
  AMGEN~ 

Product:  AMG 592  
Protocol Number:  20170103  
Date:  25 June 2020  Page 37 of 97 
CONFIDENTIAL   7.1.3 Medical Devices 
There are no investigational medical device(s) used in this study . 
Other non-investigational medical devices may be used in the conduct of this study as 
part of standard care. 
Non-investigational medical devices (eg, syringes, sterile needles), that are 
commercially available are not usually provided or reimbursed by Amgen (except, for 
example, if required by local regulation).  The investigator will be responsible for obtaining supplies of these devices.  
7.1.4 Other Protocol-required Therapies 
There are no other protocol -r
 equired therapies . 
7.1.5 Ot her Treatment Procedures 
There are no other treatment procedures. 
7.1.6 Product Complaints 
A product complaint is any written, electronic , o r oral communication that alleges 
deficiencies related to the identity, quality, durability, reliability, safety, effectiveness, or 
performance of a drug( s) or device(s) after it is released for distribution to market or 
clinic by either Amgen or by distributors and partners for whom Amgen manufactures the 
material. 
This includes any drug(s), device(s) or combination product(s) provisioned and/or  
repackaged/modified by Amgen.  Drug(s) or device(s) includes investigational product.   Amgen will collect product complaints in this study for AMG 592.
  
Any product complaint(s) associated with an investigational product(s) , 
non
-investigational product(s) , dev ice(s), or combination product(s)  supplied by Amgen 
are to be reported according to the instructions provided in the IPIM.  
7.1.7 Excluded Tr eatments, Medical Devices, and/or Procedures During 
Study Period 
The following medications are not allowed at any time during the study : 
• investigational therapies or commercially available biologic agents  
• cytotoxic agents including:  chlorambucil, cyclophosphamide, nitrogen mustard, or 
other alkylating agents 
• live vaccines 
• systemic or topical calcineurin inhibitors (eg, tacrolimus, cyclosporine, etc.)  
Approved  
  AMGEN~ 
Product:  AMG 592  
Protocol Number:  20170103  
Date:  25 June 2020  Page 38 of 97 
CONFIDENTIAL   • T cell depleting agents (eg, antithymocyte globulin, Campath) 
• recombinant IL-2 (eg, Proleukin) 
• Topical, i ntra-articular, intramuscular, or intravenous corticosteroids, including 
adrenocorticotropic hormone 
• Intra-articular hyaluronic acid injections 
Herbal supplements, vitamins, or nutritional supplements  approved by the Amgen 
Medical Monitor will be allowed. 
7.2 Method of Treatment Assignment  
Subjects will be randomized to receive AMG 592 or placebo in a 5:2 ratio (cohorts 1, 2, 
and 3) or in a 3:1 ratio (cohorts 4 and 5) via IRT. 
Assignment to the treatment arms will be based on a computer -generated randomization 
schedule prepared by Amgen before the start of the study.  Each randomized subject will 
receive a single, unique randomization number via IRT at randomization.  The 
randomization date is to be documented in the subject’s medical record as registered in 
the IRT . 
7.3 Blinding 
The study is  double-blind.  T reatment assignment will be blinded to all subjects and site 
personnel as described below.   
7.3.1 Site Personnel Access to Individual Treatment Assignments 
A subject’s treatment assignment is to only be unblinded when knowledge of the 
treatment is essential for further clinical management of the subject on this  study .  
Unblinding at the study site for any other reason will be considered a protocol deviation.  
The Amgen Tri al Manager must be notified before the blind is broken unless 
identification of the study treatment is required for a medical emergency in which the 
knowledge of the specific blinded study treatment will affect the immediate management 
of the subject’s condition.  In this case, the Amgen Trial Manager must be notified within 24 hours after breaking the blind.  The date and reason that the blind was broken must be recorded in the source documentation and CRF, as applicable.  
Approved  
  AMGEN~ 
Product:  AMG 592  
Protocol Number:  20170103  
Date:  25 June 2020  Page 39 of 97 
CONFIDENTIAL   7.3.2 Access to Individual Subject Treatment Assignments by Amgen or 
Designees 
The Amgen early development lead will be unblinded and will monitor the study on an 
ongoing basis.  Other Amgen staff and their designees involved in the study will not be 
blinded, but will be given access to the unblinding or potentially unblinding information only when there is a need to use the information for analysis, discussion and internal 
decision-making, in particular, when concerning safety issues.  Access to treatment 
assignments and other restricted data are described in Amgen standard documents.  Unblinded individuals will ensure the keeping of the blind.  Unblinding and potentially unblinding information should not be distributed to the investigators or subjects prior to a study cohort being formally unbl inded. 
7.4 Dose Modification 
7.4.1 Dose-cohort Study Escalation/De-escalation and Stopping Rules  
7.4.1.1 Dose Level Review Meetings 
After all subjects within a cohort have had the opportunity to complete the week 4 visit, a 
DLRM will be held to review data and make dose escalation/de-escalation decisions 
(see Appendix 3). 
7.4.1.2 Dose Cohort Stopping Rules 
The following dose cohort stopping rules will be used the study.  Dosing will be stopped 
or modified as shown in Table 7-1 . 
Approved  
  AMGEN~ 
Product:  AMG 592  
Protocol Number:  20170103  
Date:  25 June 2020  Page 40 of 97 
CONFIDENTIAL   Table 7-1 .  Dose Cohort Stopping R ules 
Scenario  Action  
Any occurrence of a CTCAE version 
4.03 
Grade 3 suspected adverse event 
deemed related to investigational product drug reaction of the same system organ class (eg, hepatobiliary, 
cardiovascular) observed in ≥ 2 or 
more subjects in a single dosing the 
same c ohort . Stop dosing and convene DLRM (if event occurs outside the regularly scheduled DLRM)  
Review adverse event  and all relevant safety data for 
evidence of relationship to treatment and clinical or medical significance.  
Consider unblinding, as appropriate
a. 
Based on the DLRM members’ majority vote, one of the following recommendations may be made:  
• stop enrollment of the cohort (if applicable)  
• resume enrollment of the cohort  as planned  
• expand the cohort at the same dose  
• enrollment of the study may continue at a lower 
dose 
Based on the DLRM members ’ unanimous vote one 
of the following recommendations may be made:  
• escalate to an intermediate dose (a dose lower 
than the next planned dose)  
• escalate to the next planned dose  
Any occurrence of a CTCAE 
ve
rsion  4.03 ≥ Grade 4 or greater 
suspected adverse drug reaction  Stop dosing additional subjects in the cohort and 
convene DLRM (if the event occurs outside the regularly scheduled DLRM).  
Review adverse event  and all relevant safety data for 
evidence of relationship to treatment and clinical or medical significance.  
Consider unblinding to determine relatedness to investigational product
a. 
If the adverse event is determined by a majority vote of the DLRM members to be related to the study drug and clinically or medically significant, recommend 
that no further doses should be administered at this dose and no dose escalation should proceed.  Recommend that enrollment of the study continue at a lower dose or a lower dose cohort may be added to the study. 
Otherwise, based on the majority vote of the DLRM 
members, one of the following recommendations may be made:  
• resume enrollment of the cohort as planned  
• expand the cohort at the same dose  
• continue enrollment of the study at a lower dose 
or add a lower dose cohort to the study  
DLRM  = Dose Level Review Meeting; CTCAE = common terminology criteria for adverse events . 
a Subject’s treatment assignment should only be unblinded when knowledge of the treatment is essential for 
the further management of the subject or may impact the safety of subjects currently enrolled or of 
subjects in subsequent cohorts.  A decision to stop dosing will not occur without unblinding of the subject’s 
treatment assignment.  
Approved  
  AMGEN~ 
Product:  AMG 592  
Protocol Number:  20170103  
Date:  25 June 2020  Page 41 of 97 
CONFIDENTIAL   7.4.2 Dosage Adjustments, Delays, Rules for Withholding or Restarting, 
Permanent Discontinuation 
7.4.2.1 Amgen Investigational Product:  AMG 592  
No dosage adjustments are allowed in the study .  
7.4.3 Hepatotoxicity Stopping and Rechallenge Rules 
Refer to Appendix 7 for details regarding drug-induced liver injury (DILI) guidelines, as 
specified in the Guidance for Industry Drug-Induced Liver Injury:  Premarketing Clinical 
Evaluation, July 2009.  
7.5 Preparation/Handling/Storage/Accountability  
Guidance and information on preparation, handling, storage, accountability, destruction, 
or return of the investigational product during the study are provided in the IPIM.  
7.6 Treat ment Compliance 
Subjects will receive the SC doses of study drug (AMG 592 or placebo)  at the research 
facility administered by qualified study personnel for the duration of the study . 
7.7 Treatment of Overdose 
The effects of overdose of AMG 592 are not known. 
7.8 Prior and Concomitant Treatment 
7.8.1 Prior Treatment 
Prior therapies that were being taken/used from 6 months  pri or to enrollment through the 
first dose of investigational product will be collected.  For S LE related therapies collect 
full history of prior treatment.  For pr ior therapies collect therapy name, indication, dose, 
unit, frequency, route, start date and stop date.  
7.8.2 C oncomit ant Treatment 
Throughout the study, investigators may prescribe any concomitant medications or 
treatments deemed necessary to provide adequate supportive care except for those 
listed in Section 7.1.7.  
Concomitant medications  are to be c ollected from first dose of investigational product 
through the end of safety follow -up per iod.  Collect therapy name, indication, dose, unit, 
frequency, route, start date and stop date. 
7.8.2.1 SLE Therapies 
Subj
ects who were receiving treatment with systemic SLE therapies must maintain a 
stable dose and the same route of administration through the end of study .  No new 
systemic SLE therapies may be initiated during the study. 
Approved  
  AMGEN~ 
Product:  AMG 592  
Protocol Number:  20170103  
Date:  25 June 2020  Page 42 of 97 
CONFIDENTIAL   7.8.2.2 Corticosteroids 
For subjects entering the study while taking oral steroids, no dose adjustments are 
allowed for 12 weeks.  After week 12 new corticosteroids administered by any route may 
be added or dose adjusted per investigator judgement.  
8. Discontinuation Criteria 
Subjects have the right to withdraw from investigational product and/or other 
protocol -r equired therapies, protocol procedures, or the study as a whole at any time 
and for any reason without prejudice to their future medical care by the physician or at the institution. 
The investigator and/or sponsor can decide to withdraw a subject(s) from investigational 
product, device, and/or other protocol -r
 equired therapies, protocol procedures, or the 
study as a whole at any time prior to study completion for the reasons listed in 
Sections  8.1,  8.2.1, and 8.2.2.  
8.1 Discont inuation of Study Treatment 
Subjects (or a legally acceptable representative) can decline to continue receiving investigational product and/or other protocol -r
 equired therapies or procedures at any 
time during the study but continue participation in the study.  If this occurs, the 
investigator is to discuss with the subject the appropriate processes for discontinuation 
fr
om investigational product or other protocol -r equired therapies and must discuss with 
the subject the possibilities for continuation of the Schedule of Activities (see Table 2 -1, 
Table 2-2 ) i ncluding different options of follow -up (eg, in person, by phone/mail, through 
family/friends, in correspondence/communication with other treating physicians, from the review of medical records) and collection of data, including endpoints , a
 dverse events , 
disease-related events , and m ust document this decision in the subject’s medical 
records .  Subjects who have discontinued investigational product and/or other 
pr
otocol -r equired therapies or  procedures should not be automatically removed from the 
study.  Whenever safe and feasible, it is imperative that subjects remain on-study to 
ensure safety surveillance and/or collection of outcome data. 
Subjects may be eligible for continued treatment with Amgen investigational product(s) 
and/or other protocol -r equired therapies by a separate protocol or as provided for by the 
local country’s regulatory mechanism, based on parameters consistent with Appendix 3.  
Approved  
  AMGEN~ 
Product:  AMG 592  
Protocol Number:  20170103  
Date:  25 June 2020  Page 43 of 97 
CONFIDENTIAL   Reasons for removal from protocol -required investigational product(s) or procedural 
assessments include any of the following: 
• Decision by  Sponsor  
• Lost to fol low-up 
• Death 
• Ineligibility  deter mined 
• Protocol  dev iation  
• Non- compliance 
• Adverse ev ent 
• Subject r equest 
• Disease flare requiring treatment not allowed in the protocol (eg, colitis, asthma)  
8.2
 Discontinuation From the Study  
Withdrawal of consent for a study means that the subject does not wish to receive 
further protocol -r equired therapies or procedures, and the subject does not wish to or is 
unable to continue further study  parti cipation.  Subject data up to withdrawal of consent 
will be included in the analysis of the study, and where permitted, publicly available data 
can be included after withdrawal of consent.  The investigator is to discuss with the 
subject appropriate procedures for withdrawal from the study  and m us t document the 
subject’s decision to withdraw in the subject’s medical records . 
If a s
ubject withdraws from the study, he/she may request destruction of any samples 
taken and not tested, and the investigator mus t notify  Amgen accordingly (see Appendix 
6 for further details).  R efer to the Schedule of Activities  (Table 2-1  and Table 2-2 ) for 
data to be collected at the time of study discontinuation and follow -up and for  any further 
evaluations that need to be completed. 
8.2.1 Reasons f or Removal From Washout, Run-in or Invasive Procedures  
Not applicable to this study.  
8.2.2 Reasons f or Removal From Study  
Reasons for removal of a subject from the study are: 
• Decision by  sponsor  
• Withdrawal  of c onsent from study  
• Death 
• Lost to fol low-up 
Approved  
  AMGEN~ 
Product:  AMG 592  
Protocol Number:  20170103  
Date:  25 June 2020  Page 44 of 97 
CONFIDENTIAL   8.3 Lost to Follow -up 
A subject will be considered lost to follow -up i f he or she repeatedly fails to return for 
scheduled visits and is unable to be contacted by the study site.  
The following actions must be taken if a subject fails to return to the clinic for a required 
study visit: 
• The site must attempt to contact the subject and reschedule the missed visit as soon 
as
 possible and counsel the subject on the importance of maintaining the assigned 
visit schedule and ascertain whether or not the subject wishes to and/or is able to 
continue in the study. 
• In cases i n which the subject is deemed lost to follow -up, the investigator or 
designee must make every effort to regain contact with the subject (where possible, 
3 telephone calls and, if necessary, a certified letter to the subject’s last known 
mailing address or local equivalent methods).  These contact attempts are to be 
documented in the subject’s medical record. 
• If the s ubject continues to be unreachable, he/she will be considered to have 
w
ithdrawn from the study with a primary reason of lost to follow-up.  
• For s ubjects who are lost to follow-up, the investigator can search publicly available 
records (w here permitted) to ascertain survival status.  This ensures that the data set(s) produced as an outcome of the study is/are as comprehensive as possible.  
9. Stud
 y Assessments and Procedures 
Study procedures and their time points are summarized in the Schedule of Activities 
(see Table 2-1  and Table 2-2 ).  
As protocol waivers or exemptions are not allowed if an enrolled subject is subsequently 
determined to be ineligible for the study, this  mus t be discussed with the sponsor 
immediately upon occurrence or awareness to determine if the subject is to continue or discontinue study treatment. 
Adherence to the study design requirements, including those specified in the Schedule 
of Activities, is essential and required for study conduct.  
9.1 Gener
 al Study Periods 
9.1.1 Screening, Enrollment and/or Randomization  
Informed consent must be obtained before completing any screening procedure or discontinuation of standard therapy for any disallowed therapy.  After the subject has signed the informed consent form, the site will register the subject in the IRT  and screen 
the subject in order to assess eligibility for participation.  The screening window is up to 
28 days . 
Approved  
  AMGEN~ 
Product:  AMG 592  
Protocol Number:  20170103  
Date:  25 June 2020  Page 45 of 97 
CONFIDENTIAL   All screening evaluations must be completed and reviewed to confirm that potential 
subjects meet all eligibility criteria.  The investigator will maintain a screening log to record details of all subjects screened and to confirm eligibility or record reasons for 
screening failure, as applicable.  
If a subject has not met all eligibility criteria at the end of the screening period, the 
subject will be registered as a screen fail.  Screen fail subjects may be eligible for 
re-screening 2 times. 
Rescreen subjects must first be registered as screen failures in IR T and subsequently 
registered as rescreens.  Once the subject is registered as rescreened, a new 28-day 
screening window will begin.  Subjects will retain the same subject identification number assigned at the original screening.  Subjects rescreening within the original 28-day screening period only need to repeat the assessment(s) that did not originally meet the 
eligibility criteria; all other initial screening assessments do not need to be repeated.  
Subjects rescreening after the original 28-day screening period has ended must repeat all screening procedures including being re-consented.  However, a tuberculosis test 
that was negative at the original screening does not need to be repeated as long as the 
subject has not had exposure to active tuberculosis after the original screening 
tuberculosis test was completed. 
9.1.2 Treatment Period 
Visits will occ ur per the Schedule of Activities ( Table 2-1 ).  On -study visits may be 
completed within a visit window of ± 1 day from the scheduled dose date.  The date of 
the first dose of investigational product is defined as day  1.  All subsequent doses and 
study visits will be scheduled based on the day  1 date.  Investigational product should be 
administered after all other study procedures have been completed, except at day 1 and 
week 12 of the study per the Schedule of Activities ( Table 2-1 ). 
If a subject discontinues investigational product early then he/she should complete an early termination visit as outlined in the Schedule of Activities ( Table 2-1  and Table 2 -2).  
9.1.3 Follow -up/Safety Follow -up/End of Study  
After the 12 week treatment period, subjects will be followed for an additional 6 weeks 
up until week 18 for collection of additional safety, PK and PD data as described in the Schedule of Activities ( Table 2-2 ).  In the event that a subject terminates the study early 
(ie, prior to week 18 ), a safety follow -up visit (6 weeks ± 3 days after the last dose of 
investigational product) will be performed for collection of adverse events, serious 
Approved  
  AMGEN~ 
Product:  AMG 592  
Protocol Number:  20170103  
Date:  25 June 2020  Page 46 of 97 
CONFIDENTIAL   adverse events, disease -related events , ECG , hematology, and concomitant 
medications only . 
9.2 Description of General Study Assessments and Procedures 
The sections below provide a description of the individual study procedures for required 
time points.  
9.2.1 Gener al Assessments  
9.2.1.1 Informed Consent 
All subjects must sign and personally date the IRB/IEC and Amgen approved informed 
consent before any study -specific procedures are performed. 
9.2.1.2 Demographics 
Demographic data c ol lection including sex, age, race, and ethnicity will be collected in 
order to study their possible association with subject safety and treatment effectiveness.  Additionally , dem
 ographic data will be used to study the impact on biomarkers variabili ty 
and PK of the pr otocol -required therapies.  
9.2.1.3 Medical H istory  
The Investigator or designee will collect a relevant medical and surgical history that 
started within 5 years or as  necessary for chronic or co-morbid conditions prior to 
enrollment through the start of the adverse event reporting period.  Medical history will 
include information on the subject's concurrent medical conditions.  Record all findings 
on the medical histor y CRF.   In addition to the medical history above, SLE history must 
date back to the original diagnosis.  The current toxicity grade will be collected for each 
condition that has not resolved. 
9.2.1.4 Physical Examination  
Physical examination wi ll be performed as per standard of care.  Physical examination 
findings should be recorded on the appropriate CRF (eg, medical history, event). 9.2.1.5 Ph
 ysical Measurements 
Weight in kilograms and height in centimeters should be measured without shoes . 
9.2.1.6 Substance Abuse History   
Obtain a detailed history of prior and/or concurrent use of alcohol and of nicotine or 
tobacco containing products . 
Approved  
  AMGEN~ 
Product:  AMG 592  
Protocol Number:  20170103  
Date:  25 June 2020  Page 47 of 97 
CONFIDENTIAL   9.2.2 Efficacy Assessments 
9.2.2.1 Systemic Lupus Erythematosus Disease Activity Index- 2000  
The systemic lupus erythematosus disease activity index -2000 (SLEDAI-2K ) is a global 
index that evaluates disease activity and includes 24 items collecting specific 
manifestations in 9 organ systems:  neurological, musculoskeletal, renal, mucocutaneous, general, heart, respiratory, vascular, and hematological .  The maximum 
score is 105.   
A SLEDAI score will be used for eligibility purposes but the anti -dsDNA antibodies and 
serum complement will not count towards the total score.  After  screening, anti -dsDNA 
antibodies and serum complement will be counted toward the total SLEDAI-2K score. 
Systemic lupus erythematosus disease activity index-2000 descriptors will be scored 
based on a review of medical history, physical examination, and clinical laboratory 
findings.  Findings should reflect activity during the 10 days prior to the current visit.   
9.2.3 Safety Assessments 
Planned time points for all safety assessments are listed in the Schedule of Activities  
(Table 2-1  and
  Table 2-2 ). 
9.2.3.1 Adver se Events 
9.2.3.1.1 Time Period and Frequency for Collecting and Reporting Safety 
Event Information 
9.2.3.1.1.1  Disease-related Events 
Disease-related events are defined in Appendix 4.  
The investigator is responsible for ensuring that all disease-related events observed by 
the investigator or reported by the subject that occur after the first dose of investigational product(s)/study treatment/protocol -r
 equired therapies through the safety follow -up visit 
are recorded usi ng the Event CRF.   
All serious disease-related events will be recorded and reported to the sponsor or designee within 24 hours.  The investigator will submit any updated serious disease-related event data to the sponsor within 24 hours of it being available. 
Disease-related events assessed by the investigator to be more severe than expected 
and/or related to the investigational product(s)/study treatment/protocol -r
 equired 
therapies, and determined to be serious, must be reported on the Event CRF as serious 
adverse events  and r ec orded and reported per Sections  9.2.3.1.1.3 and Appendix 4.  
Approved  
  AMGEN~ 
Product:  AMG 592  
Protocol Number:  20170103  
Date:  25 June 2020  Page 48 of 97 
CONFIDENTIAL   Disease-related events pre-defined for this study include:  lupus -related joint pain, joint 
stiffness, joint swelling, rash, alopecia, and mucosal ulcers . 
9.2.3.1.1.2  Adver se Events 
The adverse event grading scale to be used for this study will be the CTCAE and is 
described in  Appendix 4.  
The investigator is responsible for ensuring that all adverse events observed by the investigator or reported by the subject that occur after first dose of investigational product through the safety follow-up visit are reported using the Event CRF. 
9.2.3.1.1.3  Ser
 ious Adverse Events 
The investigator is responsible for ensuring that all serious adverse events observed by 
the investigator or reported by the subject that occur after signing of the informed 
consent through safety follow-up visit are reported using the Event CRF. 
All serious adverse events will be collected, recorded and reported to the sponsor or 
designee within 24 hours , as indicated in Appendix 4.   The i nvestigator will submit any 
updated serious adverse event data to the sponsor within 24 hours  of it being available. 
The criteria for grade 4 in the CTCAE grading scale differs from the regulatory criteria for serious adverse events.  It is left to the investigator’s judgment to report these grade 4 abnormalities as serious adverse events.  
9.2.3.1.1.4  Ser
 ious Adverse Events After the Protocol-required Reporting 
Period 
There is no requirement to monitor study subjects for serious adverse events following the protocol -requi
 red reporting period or after end of study.  However, these serious 
adverse events can be reported to Amgen.  Per local requirements in some countries, 
investigators are required to report serious adverse events that they become aware of 
after end of study.  If serious adverse events are reported, the investigator is to report them to Amgen within 24 hours following the investigator’s knowledge of the event. 
Serious adverse events reported outside of the protocol -r
 equired reporting period will be 
captured within the safety database as clinical trial cases and handled accordingly based 
on relationship to investigational product.  
The method of recording, evaluating, and assessing causality of adverse events, 
disease-related events, and serious adverse events and the procedures for completing and transmitting serious adverse event reports are provided in Appendix 4.  
Approved  
  AMGEN~ 
Product:  AMG 592  
Protocol Number:  20170103  
Date:  25 June 2020  Page 49 of 97 
CONFIDENTIAL   9.2.3.1.2 Method of Detecting Adverse Events and Serious Adverse Events 
Care will be taken not to introduce bias when detecting adverse events and/or serious 
adverse events.  Open-ended and non-leading verbal questioning of the subject is the preferred method to inquire about adverse event occurre nc
 e. 
9.2.3.1.3 Follo w- up of Adverse Events and Serious Adverse Event s 
After the initial adverse event/serious adverse event report, the investigator is required to 
proactively follow each subject at subsequent visits/contacts.  All adverse events and 
serious adverse events  will be followed until resolution, stabilization, until the event is 
otherwise explained, or the subject is lost to follow-up (as defined in Section 8.3).  Further information on follow-up procedures is given in Appendix 4.  
All new information for previously reported serious adverse events must be sent to 
Amgen within 24 hours following knowledge of the new information.  If specifically 
requested, the investigator may need to provide additional follow -up i
 nformation, such as 
discharge summaries, medical records, or extracts from the medical records.  Information provided about the serious adverse event must be consistent with that 
recorded on the Event CRF. 
9.2.3.1.4 Regulat
 ory Reporting Requirements for Serious Adverse Events 
If subject is permanently withdrawn from protocol -r equired therapies because of a 
serious adverse event, this information must be submitted to Amgen.  
Prompt notification by the investigator to the sponsor of serious adverse events is 
essential so that legal obligations and ethical responsibilities towards the safety of subjects and the safety of a study treatment under clinical investigation are met.  
The sponsor has a legal responsibility to notify both the local regulatory authority and 
other regulatory agencies about the safety of a study treatment under clinical investigation.  The sponsor will comply with country -s
 pecific regulatory requirements 
relating to safety reporting to the regulatory authority, IRBs/IECs, and investigators.  
Individual safety reports must be prepared for suspected unexpected serious adverse reactions (SUSAR s) ac
 cording to local regulatory requirements and sponsor policy and 
forwarded to investigators as necessary.  
An investigator who receives an individual safety report describing a serious adverse event or other specific safety information (eg, summary or listing of serious adverse 
events) from the sponsor will file it along with the Investigator’s Brochure and will notify 
the IRB/IEC, if appropriate according to local requirements. 
Approved  
  AMGEN~ 
Product:  AMG 592  
Protocol Number:  20170103  
Date:  25 June 2020  Page 50 of 97 
CONFIDENTIAL   To comply with worldwide reporting regulations for serious adverse events, the treatment 
assignment of subjects who develop serious, unexpected, and related adverse events may be unblinded by Amgen before submission to regulatory authorities.  Aggregate 
analyses may also be unblinded by the Safety Assessment Team (SAT) as appropriate.  
Investigators will receive notification of related serious adverse events reports sent to regulatory authorities in accordance with local requirements. 
9.2.3.1.5 Pr
 egnancy and Lactation 
Details of all pregnancies and/or lactation in female subjects and, female partner s of 
male subjects will be collected after the start of study treatment and until 6 week s after 
the last dose of investigational product.  
If a pregnancy is reported, the investigator is to inform Amgen within 24 hours of learning 
of the pregnancy and/or lactation and is to follow the procedures outlined in Appendi x 5.  
Amgen Global Patient Safety will follow-up with the investigator regarding additional information that may be requested.  
Abnormal pregnancy outcomes (eg, spontaneous abortion, fetal death, stillbirth, congenital anomalies, and ectopi
 c pregnancy) are considered serious adverse events. 
Further details regarding pregnancy and lactation are provided in Appendi x 5. 
9.2.3.2 Vit al Signs 
The following measurements must be performed:  systolic/diastolic blood pressure, heart rate, respiratory rate, and temperature.  Subject must be in a supine position in a rested 
and calm state for at least 5 minutes before blood pressure assessments are conducted.  If the subject is unable to be in the supine position, the subject should be in most recumbent position as possible.  The position selected for a subject should be the same 
that is used throughout the study and documented on the vital sign CRF.  The 
temperature location selected for a subject should be the same that is used throughout the study and documented on the vital signs CRF.  Record all measurements on the vital 
signs CRF . 
9.2.3.3 Electrocardiograms 
At day -1 (baseline) ECGs should be performed,  prior to blood draws or other invasive 
procedures.  Each ECG must include the following measurements:  QRS, QT, QTc, RR, 
and PR intervals.   
Single ECG s will be collected at screening and after day -1 (baseline) as outlined in the 
Schedule of Activities ( Table 2-1 ).  Subject must be in supine position in a rested and 
Approved  
  AMGEN~ 
Product:  AMG 592  
Protocol Number:  20170103  
Date:  25 June 2020  Page 51 of 97 
CONFIDENTIAL   calm state for at least 5 minutes before ECG assessment is conducted.  If the subject is 
unable to be in the supine position, the subject should be in most recumbent position as 
possible.  The ECG should be performed prior to blood draws or other invasive 
procedures and must include the following measurements:  heart rate, QRS, QT, QTc, 
and PR intervals. 
The PI or designated site physician will review all ECGs.  Once signed, the original ECG 
tracing will be retained with the subject's source documents.  At the request of the 
sponsor, a copy of the original ECG will be made available to Amgen.  Standard ECG machines should be used for all study-related ECG requirements.  Amgen will provide standard ECG machines for use by the site. 
9.2.3.4 Home Healthcare Services 
The investigator may utilize a qualified home healthcare service provider to conduct the 
procedures required during study visits, subject to the investigator’s direction and 
sponsor’s approval . 
The study may  include up to 11 home visits, including Week 1, Days 1 
(6 hours  postdose and 12 hours postdose), 2, 3, 4, and 11, and Week 12, Days 85 
(6 hours postdose and 12 h ours postdose), 86, 87 and 88.  In addition to the 
assessments listed below, adverse events, serious adverse events, and disease-related 
events will be collected as per the Schedule of Activities ( Table 2-1 ). 
Home visits on Day 1 will include:  
• biologic sample collection ( PK sampling)  
• collection of vital signs  
• assessment of changes in signs, symptoms, and concomitant medications  
Home visits on Days 2, 3, 4, and 11 will include:  
• biologic sample collection (PK and biomarker  sampling)  
• assessment of substance use  
• collection of vital signs  
• assessment of changes in signs, symptoms , and concomitant medications  
Approved  
  AMGEN~ 
Product:  AMG 592  
Protocol Number:  20170103  
Date:  25 June 2020  Page 52 of 97 
CONFIDENTIAL   In addition, on Days 2, 4, and 11, PD samples will also be drawn; on Day 2 hematology 
sample will also be drawn. 
Home visits on Day 85 will include:  
• biologic sample collection (PK sampling)  
• collection of vital signs  
• assessment of changes in signs and symptoms  
Home visits on Days 86, 87, and 88 will include:  
• biologic sample collection (PK sampling)  
• assessment of substance use  
• collection of vital signs  
• assessment of changes in signs, symptoms , and concomitant medications  
In addition, on Day 86 a single ECG will be collected.  
9.2.4 Clinical Laboratory Assessments 
All screening and on-study laboratory samples will be processed and sent to the central 
laboratory with the exception of urine pregnancy, PPD, and Quantiferon (may be done by central or local laboratory).  The central laboratory will be responsible for all screening and on-study serum chemistry, hematology, serum pregnancy, urinalysis, hepatitis  C 
antibody, hepatitis  B surface antigen and core antibody, and any other laboratory tests 
required.  Urine pregnancy  and PPD testing, if applicable, will be performed locally with 
kits provided by the central laboratory (except PPD).  If Quantiferon testing is performed locally, the central laboratory will also provide kits.  The results of this testing will be 
maintained in the source documents at the site.  
Subjects will abstain from strenuous exercise for 72 hours before each blood collection 
for clinical laboratory tests. 
Amgen or designee will be responsible for biomarker and pharmacogenetic 
assessments, and the central laboratory will ship the samples to Amgen or a specialty 
laboratory for assay (depending on the assessment).  The central laboratory will provide 
a study manual that outlines handling, labeling, and shipping procedures for  all samples.  
All blood samples will be obtained by venipuncture before investigational product administration.  The date and time of sample collection will be recorded in the source 
documents at the site.  
Approved  
  AMGEN~ 
Product:  AMG 592  
Protocol Number:  20170103  
Date:  25 June 2020  Page 53 of 97 
CONFIDENTIAL   Refer to Appendix 2 for the l ist of clinical laboratory tests to be performed and to the 
Schedule of Activities for the timing and frequency.  
The investigator is responsible for reviewing laboratory test results and recording any 
clinically relevant changes occurring during the study in the Event CRF.  The investigator 
must determine whether an abnormal value in an individual study s ubjec t represents a 
clinically significant change from the subject’s baseline values.  In general, abnormal laboratory findings without clinical significance (based on the investigator's judgment) 
are not to be recorded as adverse events.  However, laboratory value changes that 
require treatment or adjustment in current therapy are considered adverse events.  Where applicable, clinical sequelae (not the laboratory abnormality) are to be recorded as the adverse event. 
All protocol -requi
 red laboratory assessments, as defined in Appendix 2, must be 
conducted in accordance with the laboratory manual and the Schedule of Activities.  After baseline, PK/PD parameters that could unblind the study will not be reported to 
inv
estigative sites or other blinded personnel until the study has been unblinded.   
9.2.4.1 Pregnancy Testing 
A highly  sensitive serum pregnancy test will be c ompleted at screening and a urine 
pregnancy test will be completed at baseline prior to ini tiation of investigational product 
for females of childbearing potential.   
Note:  Females who have undergone a bilateral tubal ligation/occlusion should have 
pregnancy testing per protocol requirements.  (If a female subject, or the partner of a male subject, becomes pregnant it must be reported on the Pregnancy Notification 
Worksheet, see Figur
 e 12-2 ).  Refer to Appendix 5 for c ontraceptive requirements.  
Additional pregnancy testing should be performed at monthly intervals during treatment 
with investigational product and 6 weeks (± 3 days) after the last dose of investigational 
product. 
Additional on-treatment pregnancy testing may be performed at the investigator’s discretion or as required per local laws and regulations . 
9.2.4.2
 Hum an Immunodeficiency  Virus, Hepatitis B Surface Antigen, and 
Hepatitis C Antibody  
HIV testing at screening will be performed if HIV status is unknown.  Subjects will be 
assessed for h epatitis B surface antigen and hepatitis C virus antibody  titers at 
screening (see Section 6.2 ).  The results of these tests must be negative for inclusion in 
Approved  
  AMGEN~ 
Product:  AMG 592  
Protocol Number:  20170103  
Date:  25 June 2020  Page 54 of 97 
CONFIDENTIAL   the study and will be documented in the source document but will not be recorded on the 
electronic CRF  (eCRF) . 
9.2.4.3 Prespecified Biomarker Assessments 
9.2.4.3.1 C3 and C4 Complement and Anti-dsDNA  
Serological tests may be useful in assessing disease activity  in SLE.  Recent studies 
have shown an increase  in C3, C4 complement ( Humrich et al, 2015, He et al, 2016) 
and a reduction in anti - dsDNA antibodies  (He et al, 2016) in SLE patients treated with 
low dose IL- 2.  Thus, in the current study, blood samples for the measurement of C3 and 
C4 complement and anti -dsDNA will be collected as outlined in the Schedule of Activities 
(Table 2-1  and Table 2-2 ). 
9.2.5 Pharmacokinetic Assessments 
All subjects randomized to AMG 592 will have pharmacokinetic samples assessed. 
Blood samples will be collected for measurement of serum concentrations of AMG  592 
as specified in the Schedule of Activities ( Table 2-1 , and Table 2-2 ).  Instructions for the 
collection and handling of biological samples will be provided by the sponsor.  The actual 
date and time (24-hour clock time) of each sample will be recorded. 
Drug concentration information that would unblind the study will not be reported to 
investigative sites or blinded personnel until the study has been unblinded. 
9.2.6 Pharmacodynamic Assessments 
Lymphocyte subsets:  Blood samples will be collected for all subjects at the time points 
indicated in the Schedule of Activities ( Table 2-1  and Table 2 -2).  These samples will be 
used to evaluate Treg, Tcon, and NK cells.   
Detailed instructions  on sample collection, processing, and shipping will be provided in a 
separate manual . 
9.2.7 Pharmacogenetic Assessments 
If the subject consents to the optional pharmacogenetic portion of this study, DNA 
analys es may be performed.  These optional pharmacogenetic analyses focus on 
inherited genetic variations to evaluate their possible correlation to the disease and/or responsiveness to the therapies used in this study.  The goals of the optional studies include the use of genetic markers to help in the investigation of inflammatory conditions 
and/or to identify subjects who may have positive or negative response to AMG 592.  Additional samples are not collected for this part of the study.  For subjects who consent to these analyses, DNA may be extracted. 
Approved  
  AMGEN~ 
Product:  AMG 592  
Protocol Number:  20170103  
Date:  25 June 2020  Page 55 of 97 
CONFIDENTIAL   The final disposition of samples will be described in Appendix 6.  
9.2.8 Antibody Testing Procedures 
Blood sample(s) for antibody testing are to be collected according to the time points 
specified in the Schedule of Activities  (Table 2-1  and Table 2 -2) for the measurement of 
anti-AMG 592 binding antibodies.  Samples testing positive for binding antibodies will 
also be tested for neutralizing antibodies and may be further characterized.  Additional 
blood samples may be obtained to rule out anti -AMG 592 antibodies during the study. 
Subjects who test positive for anti -AMG 592 antibodies that cross -react with and 
neutralize native human IL-2 at the final scheduled study visit will be asked to return for 
additional follow up testing.  This testing is to occur approximately every 3 months 
starting from when the site has been notified of the positive result until: (1) Interleukin-2 
neutralizing antibodies are no longer detectable; or (2) the subject has been followed for a period of at least 1 year (± 4  weeks) post administration of AMG  592.  All follow -up 
results, both positive and negative will be communicated to the sites.  This notification is 
independent of and may be in advance of the time point when the entire study is planned 
to be unblinded.  Refer to Section 7.3 for additional information regarding unblinding.  
More frequent testing (eg, every month) or testing for a longer period of time may be requested in the event of safety -related concerns.  Follow-up testing is not required 
where it is established that the subject did not receive AMG  592. 
Subjects who test positive for binding, non-neutralizing antibodies and have clinical sequelae that are considered potentially related to an anti -AMG 592 antibody response 
may also be asked to return for additional follow -up testing.  Refer to the Schedule of 
Activities ( Table 2-1  and Table 2-2 ), as applicable, for specific time points, and the 
laboratory manual for detailed collection and handling instructions. 
9.2.9 Biomarker Development  
Biomarkers are objectively measured and evaluated indicators of normal biologic 
processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention.  
Biomarker development can be useful in developing markers to identify disease 
subtypes, guide therapy, and/or predict diseas e severity.  
Amgen may attempt to develop test(s) designed to identify subjects most likely to 
respond positively or negatively to AMG 592. 
Approved  
  AMGEN~ 
Product:  AMG 592  
Protocol Number:  20170103  
Date:  25 June 2020  Page 56 of 97 
CONFIDENTIAL   Blood samples are to be collected for biomarker development at the time points 
specified in the Schedule of Activities  (Table 2-1  and Table 2 -2).  
9.2.10 Other Assessments  
9.2.10.1 T uberculosis Testing 
All subjects must receive either a PPD or Quantiferon test at screening per  Section 6.2. 
9.2.10.1.1 PPD 
If a subject does not receive a Quantiferon test, then a PPD test must be performed per 
Section 6.2.  The PPD test must be read by a trained healthcare professional 48 to 
72 hours after the test is placed.  Purified protein derivative reader must be identified on 
the delegation of authority for this responsibility . 
9.2.10.1.2 Quantiferon 
If a subject does not receive a PPD test, then a Quantiferon test must be performed per 
Section 6.2.  Please refer to the central laboratory manual for instructions on sample 
collection, processing, and shipping of samples (if applicable). 
9.2.10.1.3 Chest X -Ray  
Subjects with a positive PPD test with a history of Bacillus Calmette-Guerin vaccination 
or subjects with a positive PPD test (without a history of Bacillus Calmette-Guerin 
vaccination) or a positive or indeterminate Quantiferon test will require a chest 
radiograph including posterior -anterior and lateral views.  The radiograph report should 
be read by a radiologist or per local requirement and the report must be reviewed by the investigator before enrollment of the subject. 
9.2.10.2 Peripheral Blood Mononuclear Cell 
Blood samples will be collected for subjects in the study at the time points indicated in 
the Schedule of Activities ( Table 2-1  and Table 2 -2) for peripheral blood mononuclear 
cell (PBMC) collection.  Detailed instructions on sample collection, processing, and 
shipping will be provided in a separate manual. 
10. Statistical Considerations 
10.1 Sample Size Determination 
Within each cohort subjects will be randomized to AMG 592 or placebo in a 5:2 ratio for 
cohorts 1, 2 and 3 and in a 3:1 ratio for cohorts 4 and 5.  It is planned that approximately 
29 subjects will be enrolled with 7 subjects assigned to each cohort (5 to AMG  592 and 
2 to placebo) for cohorts 1, 2 and 3 and 4 subjects assigned to cohorts 4 and 5 (3 to 
AMG 592 and 1 to placebo) .  The total sample size may exceed 29 subjects and the 
Approved  
  AMGEN~ 
Product:  AMG 592  
Protocol Number:  20170103  
Date:  25 June 2020  Page 57 of 97 
CONFIDENTIAL   number of subjects within a cohort may exceed the planned cohort size if, following a 
DLRM recommendation, additional dosing cohorts are added and/or existing cohorts are 
expanded, or if subjects are replaced as per Section 5.2.1.  If additional subjects are 
added to a cohort the randomization ratio may not be preserved.  
The sample size is based on practical consider ations.  With 5 subjects receiving 
AMG 592 per cohorts 1, 2, and 3, there is a 76% chance of at least 1 subject 
experiencing an adverse event, if the true event rate is  25%.  The chance of at least 
1 subject experiencing an adverse event will be 67% if the event rate becomes 20%.  
With a total of 21 subjects planned to receive AMG 592 in the study , there is a 19 % 
chance of at least 1 subject experiencing an adverse event with a true event rate of 1%.  The chance of at least 1 subject experiencing an adverse event will be 66 % if the true 
event rate becomes 5%. 
10.2 Analysis Sets, Subgroups, and Covariates 
10.2.1 Analysis Sets 
10.2.1.1 Safety Analysis Set  
The safety analysis set will consist of all subjects who received at least 1  dose of 
investigational product.   Safety analysis set will be used for analyses unless otherwise 
specified.  Subjects will be analyzed according to the actual treatment received. 
10.2.1.2 Pharmacokinetic Concentration Analysis Set 
The PK concentration analysis set will contain all subjects who have received AMG 592 
and have at least one reported PK concentration . 
10.2.1.3 Pharmacokinetic Parameter Analysis Set 
The PK parameter analysis set will consist of all subjects who have received AMG  592 
and for whom at least one PK parameter can be adequately estimated. 
10.2.1.4 Pharmacodynamic Analysis Set 
The PD analysis set will consist of all subjects who have received AMG 592 or placebo , 
and for whom at least 1 PD parameters has a quantifiable baseline sample and at least 
one quantifiable post-baseline PD sample has been collected. 
10.2.2 Covariates 
There are no pre-specified covariates. 10.2.3 Subgroups 
There are no pre-specified subgroup analyses . 
Approved  
  AMGEN~ 
Product:  AMG 592  
Protocol Number:  20170103  
Date:  25 June 2020  Page 58 of 97 
CONFIDENTIAL   10.2.4 Handling of Missing and Incomplete Data 
All endpoints in the study will be analyzed as -is and no imputation is planned.  
10.3 Statistical Analyses  
The statistical analysis plan will be developed and finalized before database lock.  Below 
is a summary of the timing and methods for the planned statistical analyses.  To 
preserve study integrity, the final analysis will be conducted and reported following the 
end of study, as defined in Section 5.3.1.  
10.3.1 Planned Analyses  
There are no interim analyses planned for this study .  The final analysis will be done 
after all subjects have completed the study (ie, safety follow -up).   
10.3.2 Methods of Analyses  
10.3.2.1 General Considerations 
Descriptive statistics will be provided for selected demographics, safety, PK, PD, 
immunogenicity, efficacy, and biomarker data.  Descriptive statistics on continuous 
measurements will include means, medians, Q1, Q3, standard deviations, and ranges, 
while categorical data will be summarized using frequency counts and percentages.  Data will be presented and summarized by treatment and also by time as appropriate. 
10.3.2.2 Efficacy Analyses  
As an exploratory endpoint, SLEDAI-2K score and change from baseline will be 
provided at all time points collected. 
10.3.2.3 Safety Analyses  
10.3.2.3.1 Analyses of Primary Endpoint(s) 
The primary endpoint for this study  is safety.  Safety analysis set will be used for 
analyses included in this section.  Please refer to Section 10.3.2.3.2 to 10.3.2.3.8 for 
analyses of safety endpoints.  
10.3.2.3.2 Adverse Events and Disease-related Events 
Subject incidence of all treatment-emergent adverse events will be tabulated by system 
organ class and preferred term.  Tables of fatal adverse events, serious adverse events, adverse events leading to withdrawal from investigational product or other protocol -r
equired therapies, and significant treatment emergent adverse events will also be provided.  Subj
 ect incidence of disease-related events, fatal disease-related events, 
and device-related events, if applicable, will be tabulated by system organ class and preferred term.  
Approved  
  AMGEN~ 
Product:  AMG 592  
Protocol Number:  20170103  
Date:  25 June 2020  Page 59 of 97 
CONFIDENTIAL   10.3.2.3.3 Laboratory Test Results 
The analyses of safety laboratory endpoints will include summary statistics at selected 
time points by treatment group.  Shifts in grades of safety laboratory values between the 
baseline and the worst on-study value will be tabulated. 
10.3.2.3.4 Vital Signs 
The analyses of vital signs will include summary statistics at selected time points by 
population and treatment group.  Shifts in vital sign values between the baseline and the 
worst on-study value will be tabulated. 
10.3.2.3.5 Physical Measurements 
The analyses of physical measurements will include summary statistics at selected time 
points by treatment group. 
10.3.2.3.6 Electrocardiogram  
The ECG measurements will be performed as per standard of care for routine safety 
monitoring, rather than for purposes of assessment of potential QTc effect.  Since these evaluations may not necessarily be performed under the rigorous conditions expected to 
lead to meaningful evaluation of QTc data, summaries and statistical analyses of ECG 
measurements are not planned, and these data would not be expected to be useful for meta-analysis with data from other trials.  
10.3.2.3.7 Exposure to Investigational Product 
The number of days on investigational product and the total dose of investigational 
product will be summarized using descriptive statistics.  Subject-level data may be 
provided instead of the summary if the subject incidence is low or single dose is given. 
10.3.2.3.8 Exposure to Concomitant Medication 
Number and proportion of subjects receiving therapies of interest will be summarized by 
preferred term or category for each treatment group as coded by the World Health 
Organization Drug dictionary.  
10.3.2.4 Other Analyses  
Secondary endpoints in study include PK endpoints and immunogenicity endpoints.  Exploratory endpoints in this study include biomarker endpoints, 
efficacy endpoint, and PD endpoints. 
10.3.2.4.1 Pharmacokinetic Analysis  
Pharmacokinetic concentration data will be analyzed using PK concentration analysis set.  Individual serum concentration-time plots for AMG 592 will be 
Approved  
  AMGEN~ 
Product:  AMG 592  
Protocol Number:  20170103  
Date:  25 June 2020  Page 60 of 97 
CONFIDENTIAL   presented for each subject as well as mean concentration-time plots for each 
treatment. 
Pharmacokinetic parameters will be analyzed using PK parameter analysis set. 10.3.2.4.2 Antibody Formation 
The incidence and percentage of subjects who develop anti-AMG 592 or anti-IL-2 
antibodies (binding and if positive, neutralizing) at any time will be tabulated by 
treatment group. 
10.3.2.4.3 Exploratory Endpoints 
All exploratory endpoints will be summarized using descriptive statistics.  The 
change from baseline and/or fold change from baseline may also be summarized. 
Approved  
  AMGEN~ 
Product:  AMG 592  
Protocol Number:  20170103  
Date:  25 June 2020  Page 61 of 97 
CONFIDENTIAL   11. References  
Adams  A, MacDermott EJ, Lehman TJ. Pharmacotherapy of lupus nephritis in children: 
a recommended treatment approach.  Drugs .  2006;66:1191-1207. 
AMG 592 Investigator’s Brochure.  Thousand Oaks, CA.  Amgen Inc .  
Alcocer-Varela J , Alarcon Segovia D. Decreased production of and response to 
interleukin-2 by cultured lymphocytes from patients with systemic lupus erythematosus.  
J Clin Invest .  1982; 69:1388-1392. 
Bailey S, Neuenschwander B , Laird G  et al.  A Bayesian case study in oncology Phase 1 
combination dose-finding using logistic regression with covariates.  J Biopharm Stat.  
2009;19:469 -484. 
Bonelly M, Savitskaya A, Steiner CW, Rath E, Smolen JS, Scheinecker C. Phenotypic 
and functional analysis of CD4+ CD2-Foxp3+.  J Immunol .  2009; 82:1689-1695. 
Boyman O , Sprent J. The role of interleukin.2 during homeostasis and activation of the 
immune system.  Nat Rev Immunol .  2012; 12:180-190. 
Castela E, Le Duff F, Butori C, et al.  Effects of Low -Dose Recombinant Interleukin 2 to 
Promote T- Regulatory Cells in Alopecia Areata.  JAMA Dermatol .  2014;150(7):748-751. 
He J, Zhang X, Wei Y et al. Low -dose interleukin -2 treatment selectively modulates 
CD4(+) T cell subsets in patients with systemic lupus erythematosus.  Nat Med.  2016;   
22: 991-993. 
Humrich J, von Spee-Mayer C, Siegert E, et al. Rapid induction of clinical remission by 
low-dose interleukin-2 in a patient with refractory SLE.  Ann Rheum Dis .  2015;74: 
791-792. 
Humrich J, von Spee-Mayer, Siegert E et al. Low-dose IL-2 therapy in refractory SLE: 
results from single center phase I/IIa clinical trial  (abstract).  Arthritis Rheumatol .  
2016;68 (suppl 10). http://acrabstracts.org/abstract/low -dose- il-2-therapy -in-refractory -
sle-results -from -single-center -phase -iiia-clinical -trial/.  
International Committee of Medical Journal Editors, Uniform Requirements for Manuscripts Submitted to Biomedical Journals:  Writing and Editing for Biomedical 
Publication.  2013.  http://www.icmje.org/ 
Koreth J, Matsuoka K, Kim HT, et al.  Interleukin-2 and Regulatory T cells in 
Graft-versus -Host Disease.  N Engl J Med.  2011;365:2055-2066. 
Koreth J, Kim HT, Jones KT, et al.  Efficacy, durability, and response predictors of 
low-dose interleukin-2 therapy for chronic graft-versus -host disease.  Blood .  2016; 
128:130-137. 
Kotzin BL. Systemic lupus erythematosus.  Cell .  1996; 85:303 -306. 
Lieberman LA and Tsokos GC. The IL-2 defect in systemic lupus erythematosus disease 
has an expansive effect on host immunity .  Journal of Biomedicine and Biotechnology.   
2010. Article ID 740619. http://dx.doi.org/10.1155/2010/740619 
Linker-Israeli M, Bakke AC, Kitridou RC et al. Defective production of interleukin 1 and 
interleukin 2 in patients with systemic lupus erythematosus (SLE).  0J Immunol .  
1983; 130:2651-2655. 
Long A, Cerosaletti K, Bollyky P, et al.  Defects in IL-2R signaling contribute to 
diminished maintenance of FOXP3 expression in CD4+CD25+ regulatory T-Cells of type 
1 diabetic subjects.  Diabetes .  2010;59:407-415. 
Approved  
  AMGEN~ 
Product:  AMG 592  
Protocol Number:  20170103  
Date:  25 June 2020  Page 62 of 97 
CONFIDENTIAL   Long S, Rieck M, Sanda S, et al.  Rapamycin/IL- 2 combination therapy in patients with 
type 1 diabetes augments Tregs yet transiently impairs B -cell function.  Diabetes .  2012; 
61:2340-2348.   
Malek  TR and Castro I. Interleukin-2 receptor s ignaling: a t the interface between 
tolerance and i mmunity .  Immunity .  2010; 33:153 -165 
Matsuoka K, Koreth J, Kim HT, et al. Low -dose interleukin-2 therapy restores regulatory 
T cell homeostasis in patients with chronic graft- versus -host disease.  Sci Transl Med.  
2013;5(179). 
Myara  M, Amoura Z, Parizot C et al. Glo bal natural regulatory T cell depletion in active 
systemic  lupus erythematosus.  J Immunol .  2005; 175:8392-8400. 
Neuenschwander B; Branson M; Gsponer T. Critical aspects of the Bayesian approach 
to phase 1 cancer trials.  Stat Med.  2008;27:2420-2439. 
Rhaman A and Isenberg DA. Systemic lupus erythematosus.  N Engl J Med.  2008;358: 
929-939. 
Sadoun D, Rosenzwajg M, Jolly F, et al.  Regulatory T-Cell Responses to Low -Dose 
Interleukin-2 in HCV -Induced Vasculitis.  N Engl J Med.  2011;365:2067-2077. 
Suen JL, Li HT, Jong YJ, Chiang BL and Yen JH. Altered homeostasis of CD4+ FoxP3+ 
regulatory T-cell subpopulations  in systemic lupus erythematosus.  Immunology .  2008; 
127:196-205.  
van Steenbergen H, van Nies J, Ruyssen-Witrand A, et al. IL2RA is associated w ith 
persistence of rheumatoid arthritis.  Arthritis Research & Therapy .  2015; 17:244, 
von Spee-Mayer C, Siegert E, Abdirama D et al.  Low-dose interleukin-2 selectively 
corrects regulatory T cell defects in patients with systemic lupus erythematosus.  
Ann Rheum Dis .  2015;0:1-9. 
Yu A, Snowhite I, Vendrame F, et al. Selective IL-2 responsiveness of regulatory T cells 
through multiple intrinsic mechanisms supports the use of low -dose IL-2 therapy in type 
1 diabetes.  Diabetes .  2015;64: 2172– 2183. 
Zhang B, Zhang X, Tang  FL et al. Clinical significance of increased CD4+ CD25- Foxp3+ 
T cells in patients with new -onset systemic lupus erythematosus.  Ann Rheum Dis .  
2008;67:1037– 1040. doi:10.1136/ard.2007.083543  
Approved  
  AMGEN~ 
Product:  AMG 592  
Protocol Number:  20170103  
Date:  25 June 2020  Page 63 of 97 
CONFIDENTIAL   12. Appendices 
Approved  
  AMGEN~ 
Product:  AMG 592  
Protocol Number:  20170103  
Date:  25 June 2020  Page 64 of 97 
CONFIDENTIAL   Appendix 1 .  List of Abbreviations and Definitions of Terms 
 
Abbreviation or Term  Definition/Explanation  
ACR  Am erican College of Rheumatology  
ALP alk aline phosphatase  
ALT alani ne aminotransferase  
ANC  absol ute neutrophil count  
Anti-dsDNA  An ti-double stranded DNA  
AST asp artate aminotransferase  
AUC  area under the concentration- time curve  
AUC tau area under the concentration- time curve over a dosing interval  
BIL bi lirubin  
BLRM  Bay esian logistic regression model  
CBC  com plete blood count  
cGvHD  chr onic graft versus host disease 
CIOMS  Cou ncil for International Organizations of Medical Sciences  
CFR Cod e of Federal Regulations  
Cmax maximum observed concentration  
CRF cas e report form  
CTCAE  com mon terminology criteria for adverse events  
DILI drug-i nduced liver injury  
DLRM dos e level review meeting  
ECG  Elec trocardiogram  
EDC  elec tronic data capture  
End of Study (primary 
com
pletion)  defined as the date when the last subject is assessed or receives an intervention for the final collection of data for the 
primary endpoint(s), whether the study concluded as planned in 
the protocol or was terminated early  
End of Study (end of trial)  defined 
 as the date when the last subject is assessed or 
receives an intervention for evaluation in the study (ie, last subject last visit), following any additional parts in the study (eg, safety  follow -up), as applicable  
eCRF  elec
 tronic CRF  
FIH fi rst in h uman 
FSH fol licle stimulating hormone 
GCP  Good Clinical Practice  
GLP Good Laboratory Practices  
GVHD  graf t versus host disease  
HepCAb  hepat i tis C antibody  
HIPAA Heal th Insurance Portability and Accountability Act  
Approved  
  AMGEN~ 
Product:  AMG 592  
Protocol Number:  20170103  
Date:  25 June 2020  Page 65 of 97 
CONFIDENTIAL   Abbreviation or Term  Def inition/Explanation  
HIV Hum an Immunodeficiency Virus  
HRT horm onal replacement therapy  
ICH Int ernational Council for Harmonisation  
ICMJE  Int ernational Committee of Medical Journal Editors  
IEC Indepe ndent Ethics Committee 
IgG im munoglobin G  
IL-2 I nterleukin -2 
INR int ernational normalized ratio 
IPIM Inv estigational Product Instruction Manual  
IQR int erquartile range  
IRB Ins titutional Review Boards  
IRT int eractive response technology that is linked to a central 
computer in real time as an interface to collect and process 
information  
MAD  mul tiple ascending dose  
MDRD  Modi fication of Diet in Renal Disease  
NK cells  na tural killer cells  
NKT cells n atural killer T cells 
NOAEL  no ob served adverse effect level  
PBMC  peri pheral blood mononuclear cell  
PCR  poly merase chain reaction  
PD pharm acodynamic  
PK Pha rmacokinetic  
PPD puri fied protein derivative  
PR Interval  PR  interval is measured from the beginning of the P wave to the 
beginning of the QRS complex in the heart's electrical cycle as 
measured by ECG  
QRS interval  QR S interval is the interval between the Q wave and the S wave 
in the heart's electrical cycle as measured by ECG; represents the time it takes for the depolarization of the ventricles  
QT interval  QT
  interval is a measure of the time between the start of the 
Q wave and the end of the T wave in the heart's electrical cycle 
as measured by ECG.  
QTc interval  QT  interval corrected for heart rate using accepted methodology   
QW ever y week  
Q2W  ever y other week  
RA rheu matoid arthritis  
RBC  red blood cell  
SAT saf ety assessment team  
Approved  
  AMGEN~ 
Product:  AMG 592  
Protocol Number:  20170103  
Date:  25 June 2020  Page 66 of 97 
CONFIDENTIAL   Abbreviation or Term  Def inition/Explanation  
SC subc utaneous  
SLE sy stemic lupus erythematosus  
SLEDAI -2K Sy stemic Lupus Erythematosus Disease Activity Index 2000  
SLICC  Sy stemic Lupus International Collaborating Clinics  
Source Data  information from an original record or certified copy of the 
original r ecord containing patient information for use in clinical 
research.   The information may include, but is not limited to, 
clinical findings, observations, or other activities in a clinical trial necessary for the reconstruction and evaluation of the trial.  
Source data are contained in source documents (original records 
or certified copies).  (ICH Guideline [E6]).  Examples of source 
data include Subject identification, Randomization identification, and Stratification Value.  
SRI-4 Systemic Lupus Erythematosus Responder Index -4 
Study Day 1 defi ned as the first day that protocol -specified investigational 
product(s)/protocol -required therapies is/are administered to the 
subject  
SUSAR  su spected unexpected serious adverse reaction  
TBL to tal bilirubin  
Tcon conv entional T cell  
Teff T effector cells  
Tmax time of maximum observed concentration  
Treg regul atory T cells  
ULN uppe r  limit of normal  
US Uni ted States  
 
Approved  
  AMGEN~ 
Product:  AMG 592  
Protocol Number:  20170103  
Date:  25 June 2020  Page 67 of 97 
CONFIDENTIAL   Appendix 2 .  Clinical Laboratory Tests 
The tests detailed in Table 12-1  will be performed by the central laboratory  and/or by the 
local laboratory .  
Protocol -specific requirements for inclusion or exclusion of subjects are detailed in 
Sections 6.1 to 6.2 of the protocol.  
Additional tests may be performed at any time during the study as determined necessary 
by the investigator or required by local regulations. 
Table 12-1.   Analyte Listing 
Central Laboratory  
Chemistry  Urinalysis  Hematology  Other Labs  
Sodium  
Potassium  
Chloride  
Bicarbonate  
Total protein 
Albumin  
Calcium  
Magnesium  
Phosphorus  
Glucose BUN or Urea  
Creatinine
a 
Total bilirubin  
Direct bilirubin  
ALP 
AST (SGOT)  
ALT (SGPT)  Specific gravity  
pH 
Blood 
Protein  (reflex urine 
protein to creatinine 
ratio if +1)  
Glucose 
Ketones  
Urobilinogen  
Bilirubin  
Microscopic (reflex 
testing if abnormal)  
 
 Red blood cells  
Antinuclear antibody  
Hemoglobin 
Hematocrit  
MCV  
MCH  
MCHC  
RDW  
Reticulocytes  
Platelets  
White blood cells  
WBC Differential  
• Total neutrophils or 
segmented 
neutrophils  
• Bands  
• Eosinophils  
• Basophils  
• Lymphocytes  
• Monocytes  
 Central Laboratory :  
Quantiferonb 
Hepatitis B surface Ant
igen 
Hepatitis B core antibody  
Hepatitis C virus antibody  
HIV  
FSH
c 
Serum pregnancyd 
Anti-dsDNA  
C3 and C4 complement  
Lymphocyte subsets  
PBMC  
AMG 592 PK  
Anti-AMG 592 
antibodies  
Biomarker development  
Pharmacogenetics 
sample 
SLE drug levels  
Urine drug/alcohol 
screen   
Local Laboratory : 
U
rine Pregnancy  
PPD 
ALT = alanine aminotransferase; Anti-dsDNA  = anti-double stranded deoxyribonucleic acid; AST = aspartate 
aminotransferase; BUN = blood urea nitrogen; HIV = human immunodeficiency virus; MCH = mean 
corpuscular hemoglobin; MCHC = mean corpuscular hemoglobin concentration; MCV  = mean corpuscular 
volume; RDW = r ed cell distribution width; PBMC = p eripheral blood mononuclear cell; SGOT = serum 
glutamic -oxaloacetic transaminase; SGPT  = serum glutamic -pyruvic transaminase; WBC = white blood cell 
count; MDRD = Modification of Diet in Renal Disease; PK = pharmacokinetics; FSH = Follicle stimulating 
horm one; PPD = purified protein derivative  
a Glomerular  filtration rate will be calculated by MDRD formula  
b Quantiferon testing can be done locally or by the central laboratory  
c Can be done as a part of the clinical chemistry  
d Only at screening  
Approved  
  AMGEN~ 
Product:  AMG 592  
Protocol Number:  20170103  
Date:  25 June 2020  Page 68 of 97 
CONFIDENTIAL   After baseline, pharmacokinetics ( PK)/pharmacodynamics ( PD) parameters that could 
unblind the study will not be reported to investigative sites or other blinded personnel 
until the study has been unblinded.   
Approved  
  AMGEN~ 
Product:  AMG 592  
Protocol Number:  20170103  
Date:  25 June 2020  Page 69 of 97 
CONFIDENTIAL   Appendix 3 .  Study Governance Considerations 
Dose Level Review Meetings and Data Review Team  
Dose Level Review Meetings 
The study will employ Dose Level Review Meetings (DLRM).  The DLRM team will be 
composed of the investigator(s), Amgen Medical Monitor, and Amgen Global Safety 
Officer or designee.  Other optional Amgen representatives (eg, Amgen biostatistics 
representative, Clinical Trial Manager) may be included as appropriate.  A quorum, defined as > 50% of the participating investigators who have enrolled at least 1 subject 
in the study or their qualified designee (ie, sub-investigator or research nurse or study 
coordinator possessing hard copy documentation [eg, email] of the investigator’s vote 
regarding the dose level review), must be in attendance for the DLRM.  The DLRM will be rescheduled if a quorum is not reached.  
Voting members of the DLRM will include the Amgen medical monitor, the Amgen global 
safety officer or designated safety scientist, and all participating investigators or their 
qualified medical doctor designee(s).  The majority opinion of the investigators will count as 1 vote; the medical monitor will cast 1 vote and the global safety officer will cast 1 vote.  A majority positive vote indicating an acceptable safety profile for the 
investigational product is required to allow dose level escalation or modification and/or cohort continuation/expansion to proceed.  All available study data including demographics, medical history, concomitant medications, adverse events, electrocardiograms, vital signs, laboratory results, and emerging pharmacokinetic and pharmacodynamics data will be reviewed.  Data to be reviewed may be unqueried.  
Study investigators will be informed of DLRM dosing decisions via email notification.  
Only in the following limited circumstances, dose decisions can be made by the Amgen Medical Monitor and Amgen Global Safety Officer without convening a DLRM:  
• The Amgen Medical Monitor and Amgen Global Safety Officer may decide to begin 
the next cohort using a de-escalated dose (de-escalated from the dose level  of the 
most recent cohort), if this de-escalated dose had been previously evaluated during 
a DL RM. 
Approved  
  AMGEN~ 
Product:  AMG 592  
Protocol Number:  20170103  
Date:  25 June 2020  Page 70 of 97 
CONFIDENTIAL   Regulatory and Ethical Considerations 
This study will be conducted in accordance with the protocol and with: 
• Consensus ethical principles derived from international guidelines including the 
D
eclaration of Helsinki and Council for International Organizations of Medical 
Sciences (CIOMS) International Ethical Guidelines  
• Applicable I nter national Council for Harmoni sation (ICH) Good Clinical 
Practice (GC P) Gu idelines  
• Applicable laws and regulations 
The pr
otocol, protocol amendments, informed consent form, Investigator ’s B rochure, and 
other relevant documents (eg, subject recruitment advertisements) must be submitted to 
an Institutional Review Board/International Ethics Committee ( IRB /IEC) by the 
investigator and reviewed and approved by the IRB/IEC .  A copy of the written approval 
of the protocol and informed consent form must be received by Amgen before recruitment of subjects into the study and shipment of Amgen investigational product. 
Amgen may amend the protocol at any time.  The investigator must submit and, where 
necessary, obtain approval from the IRB
 /IEC for all subsequent protocol amendments 
and changes to the informed consent document.  The investigator must send a copy of 
the approval letter from the IRB/IEC  and amended pr otocol Investigator’s Signature 
page to Amgen prior to implementation of the protocol amendment at their site. 
The investigator will be responsible for the following: 
• Providing written summaries of the status of the study to the IRB/IEC  ann ually or 
more frequently in accordance with the requirements, policies, and procedures 
established by the IR B/IEC 
• Obtaining annual IRB/IEC appr oval/renewal throughout the duration of the study.  
Copies of the investigator’s reports and the IRB/IEC conti nuance of approval must be 
sent to Amgen 
• Notifying the IRB/IEC  of serious adverse events occurring at the site, deviations from 
the protocol or other adverse event reports received from Amgen, in accordance with 
local procedures  
• Overall conduct of the study at the site and adherence to requirements of Title 21 of 
the U
.S. Code of Federal Regulations (CFR), ICH guidelines, the IRB/IEC, and al l  
other applicable local regulations  
Approved  
  AMGEN~ 
Product:  AMG 592  
Protocol Number:  20170103  
Date:  25 June 2020  Page 71 of 97 
CONFIDENTIAL   Informed Consent Process 
An initial sample informed consent form is provided for the investigator to prepare the 
informed consent document to be used at his or her site.  Updates to the sample informed consent form are to be communicated formally in writing from the Amgen Tri
 al 
Manager to the investigator.  The written informed consent form is to be prepared in the 
language(s) of the potential patient population.  
The investigator or his/her delegated repr esentative will explain to the subject, the aims, 
methods, anticipated benefits, and potential hazards of the study before any 
protocol -s pecific screening procedures or any investigational product(s) is/are 
administered, and answer all questions regarding the study.   
Subjects must be informed that their participation is voluntary.  Subjects will then be 
required to sign a statement of informed consent that meets the requirements of 21 CFR 50, l
 ocal regulations, ICH guidelines, Health Insurance Portability and 
Accountability Act (HIPAA) requirements, where applicable, and the [IRB/IEC] or s tudy 
site.  
The medical record must include a statement that written informed consent was obtained before the subject was enrolled in the study and the date the written consent was obtained.  The authorized person obtaining the informed consent must also sign the 
informed consent form. 
The investigator is also responsible for asking the subject if the subject has a primary 
care physician and if the subject agrees to have his/her primary care physician informed of the subject’s participation in the clinical study  unles
 s it is a local requirement.  The 
investigator shall then inform the primary care physician.  If the subject agrees to such notification, the investig ator i
 s to inform the subject’s primary care physician of the 
subject’s participation in the clinical study.  If the subj ect does not have a primary care 
physician and the investigator will be acting in that capacity, the investigator is to document such in the subject’s medical record.  
The acquisition of informed consent and the subject’s agreement or refusal of his/her notification of the primary care physician is to be documented in the subject’s medical records, and the informed consent form is to be signed and personally dated by the subject and by the person who conducted the informed consent discussion.  Subj
 ect 
withdrawal of consent or discontinuation from study treatment and/or procedures must also be documented in the subject’s medical records; refer to Section 8. 
Approved  
  AMGEN~ 
Product:  AMG 592  
Protocol Number:  20170103  
Date:  25 June 2020  Page 72 of 97 
CONFIDENTIAL   Subjects must be re-consented to the most current version of the informed consent 
form(s) during their participation in the study. 
The original signed informed consent form is to be retained in  accordance with 
institutional policy, and a copy of the informed consent form(s) must be provided to the 
subject.  
A subject who is rescreened is not required to sign another informed consent form if the 
res
creening occurs within 28 days from the previous informed consent form signature 
date. 
The informed consent form will contain a separate section that addresses the use of 
remaining mandatory samples for optional exploratory research.  The investigator or authorized designee will explain to each subject the objectives of the exploratory research.  Subjects will be told that they are free to refuse to participate and may 
withdraw their specimens at any time and for any reason during the storage period.  
A separate signature will be required to document a subject’s agreement to allow any 
remaining specimens to be used for exploratory research.  Subjects who decline to participate will not provide this separate signature. 
Data Protection/Subject Confidentiality  
The investigator must ensure that the subject’s confidentiality is maintained for 
documents submitted to Amgen.  
Subject will be assigned a unique identifier by the sponsor.  Any subject records or 
datasets that are transferred to the sponsor will contain the identifier only; subject names or any information which would make the subject identifiable will not be transferred.  
On the case report form ( CRF) demo
 graphics page, in addition to the unique subject 
identification number, include the age at time of enrollment. 
For Serious Adverse Events reported to Amgen, subjects are to be identified by their 
unique subject identification number, initials (for faxed reports, in accordance with local laws and regulations), and age (in accordance with local laws and regulations).  
Documents that are not submitted to Amgen (eg, signed informed consent forms) are to be kept in confidence by the investigator, except as described below. 
In compliance with governmental regulations/ICH GCP Guidelines, it is required that the 
investigator and institution permit authorized representatives of the company, of the 
regulatory agency(s), and the IRB/IEC direct access to review the subject’s original 
Approved  
  AMGEN~ 
Product:  AMG 592  
Protocol Number:  20170103  
Date:  25 June 2020  Page 73 of 97 
CONFIDENTIAL   medical records for verification of study -related procedures and data.  Direct access 
includes examining, analyzing, verifying, and reproducing any records and reports that 
are important to the evaluation of the study.   
The investigator is obligated to inform and obtain the consent of the subject to permit 
such individuals to have access to his/her study -r elated records, including personal 
information. 
Publication Policy  
To coordinate dissemination of data from this study, Amgen may facilitate the formation 
of a publication committee consisting of several investigators and appropriate Amgen 
staff, the governance and responsibilities of which are set forth in a Publication Charter.  
The committee is expected to solicit input and assistance from other investigators and to collaborate with authors and Amgen staff, as ap
 propriate, as defined in the Publication 
Charter.  Membership on the committee (both for investigators and Amgen staff) does not guarantee authorship.  The criteria described below are to be met for every 
publication.  
Authorship of any publications resulting from this study will be determined on the bas is 
of the U
niform Requirement for Manuscripts Submitted to Biomedical Journals 
International Committee of Medical Journal Editors (ICMJE) Recommendations for the Conduct of Reporting, Editing, and Publications of Scholarly Work in Medical Journals, 
which s tates :
  
Authorship credit is to be based on:  (1)  substantial contributions to conception and 
design, acquisition of data, or analysis and interpretation of data; (2) drafting the article 
or revising it critically for important intellectual content; (3) final approval of the version to 
be published; and (4) agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.  Authors need to meet conditions 1, 2, 3, and 4. 
When a large, multicenter group has conducted the work, the group is to identify the 
individuals who accept direct responsibility for the manuscript.  These individuals must 
fully meet the criteria for authorship defined above. 
Acquisition of funding, collection of data, or general supervision of the research group, 
alone, does not justify authorship.  
Approved  
  AMGEN~ 
Product:  AMG 592  
Protocol Number:  20170103  
Date:  25 June 2020  Page 74 of 97 
CONFIDENTIAL   All persons designated as authors must qualify for authorship, and all those who qualify 
are to be listed. 
Each author must have participated sufficiently in the work to take public responsibility 
for appropriate portions of the content. 
All publications (eg, manuscripts, abstracts, oral/slide presentations, book chapters) 
based on this study must be submitted to Amgen for review.  The Clinical Trial Agreement among the institution, investigator, and Amgen will detail the procedures for, 
and timing of, Amgen’s review of publications.  
Investigator Signatory Obligations 
Each clinical study report is to be signed by the investigator or, in the case of multicenter 
studies, the coordinating investigator. 
The coordinating investigator, identified by Amgen, will be any or all of the following:  
• A recognized ex
 pert in the therapeutic area  
• An Investigator who provided significant contributions to either the design or 
i
nterpretation of the study  
• An Investigator contributing a high number of eligible subjects  
D
ata Quality Assurance 
All subject data relating to the study will be recorded on printed or electronic CRF unless 
transmitted to the sponsor or designee electronically (eg, laboratory data, centrally or 
adjudicated data).  The investigator is responsible for verifying that data entr ies are 
accurate and correct by physically or electronically signing the CRF.  
The investigator must maintain accurate documentation (source data) that supports the 
information entered in the CRF.  
The investigator must permit study -r elated monitoring, audits, IRB/IEC review, and 
regulatory agency inspections and provide direct access to source data documents.   
The sponsor or designee is responsible for the data management of this study including 
quality checking of the data.  
Clinical monitors will perform ongoing source data verification to confirm that data 
enter
ed into the CRF by authorized site personnel are accurate, complete, and verifiable 
from source documents; that the safety and rights of subjects are being protected; and 
that the study is being conducted in accordance with the currently approved protocol and 
Approved  
  AMGEN~ 
Product:  AMG 592  
Protocol Number:  20170103  
Date:  25 June 2020  Page 75 of 97 
CONFIDENTIAL   any other study agreements, ICH GCP, and all applicable regulatory requirements per 
the sponsor’s monitoring plan.  
The investigator agrees to cooperate with the clinical  moni tor to ensure that any 
problems detected in the course of these monitoring visits, including delays in completing CRFs, are resolved. 
The Amgen representative(s) and regulatory authority inspectors are responsible for 
contacting and visiting the investigator for the purpose of inspecting the facilities and, 
upon request, inspecting the various records of the clinical study (eg, CRFs and other 
pertinent data) provided that subject confidentiality is respected. 
In accordance with ICH GCP and the sponsor’s audit plans, this study may be selected 
for audit by representatives from Amgen’s Global Research & Development Compliance and Audit function (or designees).  Inspection of site facilities (eg, pharmacy, 
protocol -r
equired therapy storage areas, laboratories) and review of study -related 
records will occur to evaluate the study conduct and compliance with the protocol, 
ICH GCP, and applicable regulatory requirements. 
R
etention of study documents will be governed by the Clinical Trial Agreement. 
Case report forms  mus t be completed in English.  TRADENAMES® (if used) for 
concomitant medications may be entered in the local  langua ge.  Consult the 
country -s pecific language requirements.  
All written information and other material to be used by subjects and investigative staff must use vocabulary and language that are clearly understood. 
Source Documents 
The investigator is to maintain a list of appropriately qualified persons to whom he/she 
has delegated study duties.  All persons authorized to make entries and/or c orr
 ections 
on CRFs will be included on the Amgen Delegation of Authority Form.  
Source documents provide evidence for the existence of the subject and substantiate the integrity of the data collected.  Source documents are filed at the investigator’s site. 
Source documents are original documents, data, and records from which the subject’s 
CRF data are obtained.  These include but are not limited to hospital records, clinical and office charts, laboratory and pharmacy records, diaries, microfiches, radiographs, and correspondence.  Source documents may also include data captured in the IRT  (i
 f 
used, such as subject identification and r andom ization number) and CRF entries if the 
Approved  
  AMGEN~ 
Product:  AMG 592  
Protocol Number:  20170103  
Date:  25 June 2020  Page 76 of 97 
CONFIDENTIAL   CRF is the site of the original recording (ie, there is no other written or electronic record 
of data, such as paper questionnaires for a clinical outcome assessment). 
Data reported on the CRF or entered in the electronic CRF that are transcribed from 
source documents must be consistent with the source documents or the discrepancies 
must  be explained.  The investigator may need to request previous medical records or 
tr
ansfer records, depending on the study.  Also, current medical records must be 
available. 
The Investigator and study staff are responsible for maintaining a comprehensive and 
centralized filing system of all study -r elated (essential) documentation, suitable for 
inspection at any time by representatives from Amgen and/or applicable regulatory authorities. 
Elements to include:  
• Subject files containing completed CRFs, informed consent forms, and subject 
i
dentification list  
• Study files containing the protocol with all amendments, Investigator’s Brochure, 
c
opies of prestudy documentation, and all correspondence to and from the IRB/IEC 
and Amgen  
• Investigational product- r elated correspondence including [Proof of Receipts, 
Investigational Product Accountability Record(s), Return of Investigational Product 
for Destruction Form(s), Final Investigational Product Reconciliation Statement, as 
applicable 
• Non- investigational product(s), and/or medical device(s) or combination product(s) 
documentation, as applicable]  
• Retention of study documents will be governed by the Clinical Trial Agreement. 
S
tudy and Site Closure 
Amgen or its designee may stop the study or study site participation in the study for 
medical, safety, regulatory, administrative, or other reasons consistent with applicable 
laws, regulations, and GCP.  
Both Amgen and the Investigator reserve the right to terminate the Investigator’s participation in the study according to the Cl
 inical Trial Agreement.  The investigator is to 
notify the IRB/IEC in w riting of the study’s completion or early termination and send a 
copy of the notification to Amgen.  
Approved  
  AMGEN~ 
Product:  AMG 592  
Protocol Number:  20170103  
Date:  25 June 2020  Page 77 of 97 
CONFIDENTIAL   Subjects may be eligible for continued treatment with Amgen investigational produc t(s) 
by an extension protocol or as provided for by the local country’s regulatory mechanism.  
However, Amgen reserves the unilateral right, at its sole discretion, to determine 
whether to supply Amgen investigational product(s) and by what mechanism, after 
termination of the study and before the product(s) is/are available commercially.  
Compensation 
Any arrangements for compensation to subjects for injury or illness that arises in the 
study are described in the Compensation for Injury section of the Informed Consent that is available as a separate document. 
Approved  
  AMGEN~ 
Product:  AMG 592  
Protocol Number:  20170103  
Date:  25 June 2020  Page 78 of 97 
CONFIDENTIAL   Appendix 4 .  Safety Events:  Definitions and Procedures for Recording, 
Evaluating, Follow -up and Reporting 
Definition of Disease-related Event  
Disease- related Event Definition  
Disease -related events are events (serious or non -s erious) anticipated to occur in the study 
population due to the underlying disease.  See Sec tion 9.2.3.1.1.1  fo r the list of 
disease- related events.   All serious disease -related events will be recorded and reported to 
the sponsor or designee within 24 hours.   
D
isease -related events that would qualify as an adverse event or serious adverse event:  
o An event based on the underlying disease that is worse than expected as assessed by 
t
he investigator for the subject’s condition or if the investigator believes there is a 
causal relationship between the investigational product(s)/study 
treatment/protocol -re quired therapies and disease worsening, this must be reported as 
an adverse event or serious adverse event.  
Disease -relat ed events that do not qualify as adverse events or serious adverse events:  
o An event which is part of the normal course of disease under study (eg,  di sease 
progression in oncology or hospitalization due to disease progression) is to be reported 
as a disea se-rel ated event.   
Definition of Adverse Event 
Adverse Event Definition  
An adverse event is any untoward medical occurrence in a cl inical study subject 
irrespective of a causal relationship with the study t reatment.   
Note:  An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally 
associated with the use of a treatment, combination product, medical device or procedure.  
Events Meeting the A dve
 rse Event Definition 
Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) or other safety assessments (eg, electrocardiogram [ ECG],
  radiological scans, vital signs 
measurements), including those that worsen from baseline, that a re considered clinically 
significant in the medical and scientific judgment of the investigator (ie, not related to progression of underlying disease).  
Exacerbation of a chronic or intermittent pre -exi
 sting condition including either an increase 
in frequency and/or intensity of the condition.  
New conditions detected or diagnosed after study treatment administration even though it may have been present before the start of the study.  
Signs, symptoms, or the clinical sequelae of a suspected drug -dr
 ug interaction.  
Signs, symptoms, or the clinical sequelae of a suspected overdose of either study treatment or a concomitant medication.  Overdose per se will not be reported as an adverse event/serious adverse event unless it is an intentional overdose taken with 
possible suicidal/self -har
 ming intent.  Such overdoses are to be reported regardless of 
sequelae.  
“Lack of efficacy” or “failure of expected pharmacological action” per se will not be reported as an adverse event or serious adverse event.  Such instances will be captured in the 
efficacy assessments.  However, the signs, symptoms, and/or clinical sequelae resulting from lack of efficacy will be reported as adverse event or serious adverse event if they fulfill 
the definition of an adverse event or serious adverse event.  
Approved  
  AMGEN~ 
Product:  AMG 592  
Protocol Number:  20170103  
Date:  25 June 2020  Page 79 of 97 
CONFIDENTIAL   Events NOT Meeting the Adverse Event Definition  
Medical or surgical procedure (eg, endoscopy, appendectomy):  the condition that leads to 
the procedure is the adverse event.  
Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospital).  
Anticipated day -to-d ay fluctuations of pre- existing disease(s) or condition(s) present or 
detected at the start of the study that do not worsen.  
Definition of Serious Adverse Event 
A Serious Adverse Event is defined as any untoward medical occurrence that meets 
at least 1 of the following serious criteria: 
R
esults in death (fatal)  
Immediately  l ife-threatening 
The term “life -thr eatening” in the definition of “serious” refers to an event in which the 
subject was at risk of death at the time of the event.  It does not refer to an event, which hypothetically might have caused death, if it were more severe.  
Requires in -pat
 ient hospitalization or prolongation of existing hospitalization 
In general, hospitalization signifies that the subject has been detained (usually involving at 
least an overnight stay) at the hospital or emergency ward for observation and/or treatment 
that would not have been appropriate in the physician’s office or outpatient setting.  
Complications that occur during hospitalization are an adverse event.  If a complication prolongs hospitalization or fulfills any other serious criteria, the event is serious.  When in 
doubt as to whether “hospitalization” occurred or was necessary, the adverse event is to be 
considered serious.  
Hospitalization for elective treatment of a pre -exi
 sting condition that did not worsen from 
baseline is  not  considered an adverse event.  
Results in persistent or significant disability/incapacity  
The term disability means a substantial disruption of a person’s ability to conduct normal 
life functions.  
This definition is not intended to include experiences of  relatively minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, and accidental trauma (eg, sprained ankle) which may interfere with or prevent everyday life 
functions but do not constitute a substantial disru pti
 on. 
Is a congenital anomaly/birth defect  
Other medically important serious event  
Medical or scientific judgment is to be exercised in deciding whether serious adverse event 
reporting is appropriate in other situations such as important medical events that may not 
be immediately life -thr eatening or result in death or hospitalization but may jeopardize the 
subject or may require medical or surgical intervention to prevent 1 of the other outcomes 
listed in the above definition.  These events are typically  to be considered serious.  
Examples of such events include invasive or malignant cancers, intensive treatment in an 
emergency room or at home for allergic bronchospasm, blood dyscrasias or convulsions 
that do not result in hospitalization, or development of drug dependency or drug abuse.  
Approved  
  AMGEN~ 
Product:  AMG 592  
Protocol Number:  20170103  
Date:  25 June 2020  Page 80 of 97 
CONFIDENTIAL   Recording Adverse Events, Disease-related Events (if  applicable), and Serious 
Adverse Events 
Adverse Event, Disease- related Event, and Serious Adverse Event Recording 
When an adverse event, disease -rel ated event or serious adverse event occurs, it is the 
responsibility of the investigator to review all documentation (eg, hospital progress notes, 
laboratory, and diagnostics reports) related to the event.  
The investigator will then record all relevant adverse event/dis eas e-related event/serious 
adverse event information in the Event case report form ( CR F). 
o Additionally, the investigator is required to report a fatal disease- r elated event on the 
Event CRF.  
The investigator must assign the following adverse event attribut es: 
o Adverse event diagnosis or syndrome(s), if known (if not known, signs or symptoms);  
o Dates of onset and resolution (if resolved);  
o Severity (or toxicity defined below);  
o Assessment of relatedness to investigational product, other protocol -r equired 
therapies ; and 
o Action taken.  
I
f the severity of an adverse event changes from the date of onset to the date of resolution, 
rec
ord as a single event with the worst severity on the Event CRF.  
It is not acceptable for the investigator to send photocopies of the subject’s medical records 
t
o sponsor  in lieu of completion of the Event CRF page.  
If specifically requested, the investigator may need to provide additional follow -up 
i
nformation, such as discharge summaries, medical records, or extracts from the medical 
records.  In this case, all subject identifiers, with the exception of the subject number, will 
be blinded on the copies of the medical records before submission to Am gen. 
The investigator will attempt to establish a diagnosis of the event based on signs, symptoms, and/or other clinical information.  In such cases, the diagnosis (not the individual signs/symptoms) will be documented as the adverse event/serious adverse 
event.  
Evaluating Adverse Events and Serious Adverse Events 
Assessment of Severity  
The investigator will make an assessment of sev erity for each adverse event and serious 
adverse event reported during the study.  The assessment of  sev erity will be based on:  
The Common Terminology Criteria for Adverse Events (CTCAE), ver sion 4.03 which is 
available at the following location:  
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm . 
Approved  
  AMGEN~ 
Product:  AMG 592  
Protocol Number:  20170103  
Date:  25 June 2020  Page 81 of 97 
CONFIDENTIAL   Assessment of Causality  
The investigator is obligated to assess the relationship between investigational prod uct, 
protocol -required therapies,  and/ or study -mandated procedure and each occurrence of 
each adverse event/serious adverse event.  
Relatedness means that there are facts or reasons to support a relationship between 
investigational product and the event . 
T
he investigator will use clinical judgment to determine the relationship.  
Alternative causes, such as underlying disease(s), concomitant therapy, and other risk factors, as  wel
 l as the temporal relationship of the event to study treatment administration 
will be considered and investigated.  
The investigator will also consult the Investigator’s Brochure and/or Product Information, for marketed products, in his/her assessment.  
For each adverse event/serious adverse event, the investigator mu
 st document in the 
medical notes that he/she has reviewed the adverse event/serious adverse event and has provided an assessment of causality.  
There may be situations in which a serious adverse event has occurred and the investigator has minimal information to include in the initial report.  However, it is very important that the investigator always make an assessment of causality for every event 
before the initial transmission of the serious adv
 erse event data.  
The investigator may change his/her opinion of causality in light of follow -up i nformation 
and send a serious adverse event follow -up r eport with the updated causality assessment.  
The causality assessment is 1 of the criteria used when determining regulatory reporting 
requirements.  
Follow -up of Adverse Event and Serious Adverse Event 
T
he investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically indicated or as requested by Am gen to 
elucidate the nature and/or causality of the adverse event or serious adverse event as fully as possible.  This may include additional laboratory tests or investigations, histopathological examinations, or consultation with other health care professionals.  
If a subject is permanently withdrawn from protocol -re
 quired therapies because of a seri ous 
adverse event, this information must be submitted to Amgen.  
If a subject dies during participation in the study or during a recognized follow -up period, the 
investigator will provide Amgen with a copy of any post -mortem findings including 
histopatholog y. 
New or updated information will be recorded in the originally completed Event CRF.  
The investigator will submit any updated serious adverse event data to Am gen within 
24 hours of receipt of the information.  
Approved  
  AMGEN~ 
Product:  AMG 592  
Protocol Number:  20170103  
Date:  25 June 2020  Page 82 of 97 
CONFIDENTIAL   Reporting of Serious Adverse Event  
Serious Adverse Event Reporting via Electronic Data Collection Tool  
The primary mechanism for reporting serious adverse event will be the electronic data 
capture (EDC) system via the Safety Report Form.  
If the EDC system is unavailable for more than 24 hours, then the site will report the information to Amgen using an Electronic Serious Adverse Event Contingency Form (paper form; see Fi
 gure 12 -1) within 24 hours of the investi gator’s knowledge of the event . 
The site will enter the serious adverse event data into the electronic system as soon as it becomes available.  
After the study is completed at a given site, the EDC system will be taken off -li
 ne to prevent 
the entry of new data or changes to existing data.  
If a site receives a report of a new serious adverse event from a study subject or receives updated data on a previously reported serious adverse event after the EDC has been taken 
off-line, then the site can report this info r
 mation on an Electronic Serious Adverse E vent 
Contingency Fo rm (paper form; see Figure 12 -1). 
Approved  
  AMGEN~ 
Product:  AMG 592  
Protocol Number:  20170103  
Date:  25 June 2020  Page 83 of 97 
CONFIDENTIAL   Figure 12-1 .  Sample Electronic Serious Adverse Event Contingency Form  
 
Approved  
  -Electronic Seriou s Adverse Event Contingenc y Report Form 
Study# 20170103 For Restricte-d Use AMG 532 
A- on m ,-c,ort 1110 ui1 , , .. , ..... 
TIM CHl'llO~ n111,1 o,1 ab•• 1•0. ~r. 
0 1 , net :,•n,l\,ble ct.>c 1, lr!!tlT.C !OUbg;~ .)!( rrry :nc 
0 1~nct yet :iY111131)'c IN~~, 
D 1-1~ teffl <1~ c <1 ru 1111~ :w-(PJ" 
1.1$: +11111 814 ~IUJ 
1 .#TE MFORMA. TION 
1 i T 1 - --
2.&UBJEC T .. FORIIIA T10N J i'i 1 1·-1 
11 I n ·rr I I I I""·--~-......... -"""'"""" o, "" -
1r,n '-J~ D J11""'-~ • ~ e oc ~r,;lcff>lt;. a-t.oi,:,,i:k ~ ~.c-~mt 
-~411:1:: Q,o, -,_ 
i.. lalOIJI AOYEME EVENT 
l'rt!lde trle#r mt •---'- ,:,r -o1 • ...... .... , .. ---~ ... ,._ · --- -- ••ll'M'lo_,_ ,.,.,.,...... ., 'i -~N••-----,_ - - ... --- .. -· ~l'f'lldl~ - , lan, t111kb< f - -.. " -~~31¥1..~ ----,,. .. """"" ___ _ .,. -- -n -I# __ ,_.,. · -•---ti. ~ -I - -·-_.,_a,.,.,_.,u _...,. ., - ·-"·- -~--~-,_ • -· -• -• -• -· -- ·-' ,_ .,__,_ .. __ °'""-···--.c....,.-.. .. _.. ....... _.., 
4. W.:IUtlillOt~ ~ - •h~ £W"OIOIIOed-- tM;-,t't ONo ov· ••-P--•«-~ ou~o I Off Oi:rlut:iec, ~, --· ~ , -~ · I 
f..W. P.flSUQunclw~ .... ~ l'l.,,_.lofNs-.l? Ot«> OV-.•f- p1..-~•o1S-ll -• •-db--·- Caitolri'tii;OY .c O.olOO-.c ----~ ------tot••-· ,,, __ -,, .. ~- ~--.,,_ , -,_, ~ -~ ----o--· -~ ,:t--, •·--o- • -
Product:  AMG 592  
Protocol Number:  20170103  
Date:  25 June 2020  Page 84 of 97 
CONFIDENTIAL   Figure 12-1.  Sample Electronic Serious Adverse Event Contingency Form  
 
Approved  
  AdJEN 
Study # 201701! D3 
AMG 55'2 
l I Electron ic Seriol!IS Adverse Ev ent Conting ency Reporll Form 
For Reshicied Use, 
at!-MJEmel" 
J ~IDlbnleJ I I I ] I I I I ] I I ] I I ] I 
I. CCNCOl8TANT IED ICAllOIIII 411G. ..,,, Mill -.-. 1' VH I'-IN- a..-
-liluH(a] -=-llic90lilol ... -,_ '-'-- .... -,.., ""' ------IP"" ,..,,. I --,..,,. 
7_ REI.EVANT IED ICAL fllTOIRY............, dil'..., ...... ._ IIHd'__,,,....,_ _.,.rlflw""'~ 1 
I. REI.EVANT LABORA TCRYV ALUEa NHilnii ...ru1H j ,.._f" Ubol':ll lc<T-nun > 0 ~= 11 'j9, ,.__ ic..,.plalll 1 1 -
Ila I u. 
,_ -.... 
t. 0TIER FIS.IEV .AHT TEIITI-(,.,..,_tk11 ilffd,Pl'oeNil'IH j ll'19'" pko•_.....111 
ca ,~T~ R=1!. 'L.r-11il ... ,.._., -
_.,.._ 71D U Z HtS 
'Zc:13 
Product:  AMG 592  
Protocol Number:  20170103  
Date:  25 June 2020  Page 85 of 97 
CONFIDENTIAL   Figure 12-1.  Sample Electronic Serious Adverse Event Contingency Form  
 
Approved  
  AMt3EN 
Study # 201101 oo 
AMG59t2 Electronic Seriou:s Adve-,r:se Event Conti nge 111 c.y Report Form 
For Resbiictedl U'se 
I at!l!t.alel" I ~IDludlel' I 
I I I I I I I I I I I I I I I I 
1 ... CASE DElal:Pll ON ""'~ __,. ... ddllil "'- •llir.d r11 .~ Jj PltMde addlblli rnece:.:.111) '. Far md'I 
l!\ll!d h ~:n 3 whe"e rellil~ Ye. ..-, ll"l1d:le rlilini.e. 
.. ct-a .. o...,... • Tlh O.lo 
,a,,o/lrrD...,.qarlQ L\11.._,rilffi:.\l,.,,.._,_o.alfl&I.,_,,~--
~-•Cl!,.11 ""k111--"'""-.lf .... hullga:Mjlrdiu::ud1, .... ,ocv,qlld ___ ...,. ..... -....W/ttt•\11.m.qo: 
,~ 
Product:  AMG 592  
Protocol Number:  20170103  
Date:  25 June 2020  Page 86 of 97 
CONFIDENTIAL   Appendix 5 .  Contraceptive Guidance and Collection of Pregnancy and Lactation 
Information 
Study -s pecific contraception requirements for female of childbearing potential are 
outlined in Section 6.2.  
Female subjects of childbearing potential must receive pregnancy prevention counseling 
and be adv
ised of the risk to the fetus if they become pregnant during treatment and for 
6 weeks (±  3 days) after the last dose of protocol -required therapies.  
Additional medications given during the study may alter the contraceptive requirements.  
These additional medications may require female subjects to use highly effective 
methods of contraception and for an increased length of time.  In addition, male subjects may also be required to use contraception.  The investigator must discuss these contraceptive changes with the subject.  
Definition of Females of Childbearing Potential 
A female is considered fertile following menarche and until becoming post-menopausal 
unl
ess permanently sterile.  Permanent sterilization methods include hysterectomy, 
bilateral salpingectomy, and bilateral oophorectomy.  
Females  in the following categories are not considered fem ale of c hildbearing potential : 
• Premenopausal fem ale with 1 of the following:  
o Documented hysterectomy ;  
o Documented bilateral salpingectomy ; or 
o Documented bilateral oophorectomy. 
N
ote:  Site personnel documentation from the following sources is  acc eptable:  
1) review of subject’s medical records; 2) subject’s medical examination; or 
3)
 subject’s medical history interview. 
• Premenarchal  fem ale 
• Postmenopausal female 
o A postmenopausal state is defined as no menses for 12 months without an 
al
ternative medical cause.  A high follicle stimulating hormone (FSH) lev el in the 
postmenopausal range may be used to confirm a postmenopausal state in 
women not using hormonal contraception or hormonal replacement therapy  (HRT).  However, in the absence of 12 m
 onths of amenorrhea, a single 
FSH measurement is insufficient.  
o Females on HRT and whose menopausal status is in doubt will be required to 
us
e 1 of the non -hormonal highly effective contraception methods if they wish to 
continue their HRT during the study.  Otherwise, they must discontinue HRT to 
allow confirmation of postmenopausal status before study enrollment. 
Approved  
  AMGEN~ 
Product:  AMG 592  
Protocol Number:  20170103  
Date:  25 June 2020  Page 87 of 97 
CONFIDENTIAL   Contraception Methods for Female Subjects 
Highly Effective Contraceptive Methods  
Note:  Failure rate of < 1% per year when used consistently and correctly.  
• Combined (estrogen and progestogen c ontaining) hormonal contraception 
associated with inhibition of ovulation (oral, intravaginal, or transdermal)  
• Progestogen-only hor monal contraception associated with inhibition of ovulation 
(oral, injectable, implantable)  
• Intrauterine device  
• Intrauterine hormonal - releasing system  
• Bilateral tubal ligation/occlusion  
• Vasectomized partner (provided that partner is the sole sexual partner of the female 
s
ubject of childbearing potential and that the vasectomized partner has received 
medical assessment of the surgical success)  
• Sexual abstinence (defined as refraining from heterosexual intercourse during the 
enti
re period of risk associated with the study treatments; the reliability of sexual 
abstinence must be evaluated in relation to the duration of the trial and the preferred 
and usual lifestyle of the subject) 
U
nacceptable Methods of Birth Control for Fem ale Subjects 
Birth control methods that are considered unacceptable in clinical trials include:  
• Periodic abstinence (calendar, symptothermal, post-ovulation methods)  
• Withdrawal (coitus interruptus)  
• Spermicides only  
• Lactational amenorrhea  m ethod 
Collection of Pregnancy Information 
Female Subjects Who Become Pregnant 
• Investigator will collect pregnancy information on any female subject who becomes 
pr
egnant while taking protocol -r equired therapies through 6 weeks (±  3 days) after 
the last dose of investigational product. 
• Information will be recorded on the Pregnancy N oti fication Worksheet (see Figure 
12-2).  The w orksheet must be submitted to Amgen Global Patient Safety within 24 
hours of learning of a subject’s pregnancy.  (Note:  Si tes are not required to provide 
any information on the Pregnancy Notification Worksheet that violates the country 
or regions local privacy laws.)  
Approved  
  AMGEN~ 
Product:  AMG 592  
Protocol Number:  20170103  
Date:  25 June 2020  Page 88 of 97 
CONFIDENTIAL   • After obtaining the female subject’s signed authorization for release of pregnancy 
and infant health information, the investigator will collect pregnancy and infant 
health information and complete the pregnancy questionnaire for any female subject who becomes pregnant whi
 le taking protocol -required therapies through 6 weeks 
(± 3 day s) after the last dose of the study drug.  This information will be forwarded 
to Amgen Global Patient Safety.  Generally, infant follow-up will be conducted up to 
12 months after the birth of the child (if applicable). 
• Any termination of pregnancy will be reported to Amgen Global Patient Safety, 
r
egardless of fetal status (presence or absence of anomalies) or indication for 
procedure.  
• While pregnancy itself is not considered to be an adverse ev ent or serious adverse 
event, any pregnancy complication or report of a congenital anomaly or 
developmental delay, fetal death, or suspected adverse reactions in the neonate will be reported as an adverse event or serious adverse event.  Note that an el ecti
 ve 
termination with no information on a fetal congenital malformation or maternal complication is gener
 ally not considered an adverse event, but still must be reported 
to Amgen as a pregnancy exposure case. 
• If the outc o me of the pregnancy meets a criterion for immediate classification as a 
serious adverse event (eg, female subject experiences a spontaneous abortion, stillbirth, or neonatal death or there is a fetal or neonatal congenital anomaly) the 
investigator will report the event as a serious adverse event. 
• Any serious adverse event occurring as a result of a post-study pregnancy which is 
c
onsidered reasonably related to the study treatment by the investigator, will be 
reported to Amgen Global Patient Safety as described in Appendix 4.  While the 
investigator is not obligated to actively seek this information in former study 
subjects, he or she may learn of a serious adverse event through spontaneous 
reporting.  
• Any female subject who becomes pregnant while participating will discontinue 
i
nvestigational product (s ee Section 8.1  for details). 
Male Subjects W ith P artners Who Become Pregnant or Were Pregnant at the Time of 
Enrollment 
• In the event a m ale subject fathers a child during treatment, and for an additional  
6 weeks (±  3 days) after discontinuing protocol -required therapies, the information 
will be recorded on the Pregnancy Notification Worksheet.  The worksheet 
(see Figure 12-2 )  must be submitted to Amgen Global Patient Safety within 
24 hours of the site’s awareness of the pregnancy.  (Note:  S ites are not required to 
provide any information on the Pregnancy Notification Worksheet that violates the 
country or regions local privacy laws.)  
• The i nvestigator will attempt to obtain a signed authorization for release of 
pr
egnancy and infant health information directly from the pregnant female partner to 
obtain additional pregnancy information. 
• After obtaining the female partner’s signed authorization for release of pregnancy 
and i
nfant health information, the investigator will collect pregnancy outcome and 
infant health information on the pregnant partner and her baby and complete the 
pregnancy questionnaires.  This information will be forwarded to Amgen Global 
Patient Safety.  
Approved  
  AMGEN~ 
Product:  AMG 592  
Protocol Number:  20170103  
Date:  25 June 2020  Page 89 of 97 
CONFIDENTIAL   • Generally, infant follow- up will be conducted up to 12 months after the birth of the 
child (if applicable).  
• Any termination of the pregnancy will be reported to Amgen Global Patient Safety 
r
egardless of fetal status (presence or absence of anomalies) or indication for 
procedure. 
Collection of Lactation Information 
• Investigator will collect lactation information on any female subject who breastfeeds 
w
hile taking protocol -r equired therapies through 6 weeks after the last dose of 
investigational product.  
• Information will be recorded on the Lactation Notification Worksheet (see below) 
and submitted to Amgen Global Patient Safety within 24 hours of the investigator’s 
k
nowledge of event. 
• Study treatment will be discontinued if female subject breastfeeds during the study 
as
 described in exclusion criterion 22 6.  
• With the female subjects signed authorization for release of mother and infant 
heal
th information, the investigator will collect mother and infant health information 
and complete the lactation questionnaire on any female subject who breastfeeds 
while taking protocol -r equired therapies through 6 weeks after discontinuing 
protocol -r equired therapies. 
Approved  
  AMGEN~ 
Product:  AMG 592  
Protocol Number:  20170103  
Date:  25 June 2020  Page 90 of 97 
CONFIDENTIAL   Figure 12-2 .  Pregnancy and Lactation Notification Worksheet 
 
Approved  
  Amgen Proprietary -Confidonlia l AtttGEH0 
Pregnancy Notification Form 
Study Design: lntervent ional D Observationa l (If Observationa l: D Prospective D Retrospective ) 
2. Contact Information 
Investigator Name____________________ _ Site# ____________ _ 
Phone{_~---------Fax(_) ________ _ Email ____________ _ 
Institution ________________________________________ _ 
Address 
4. Amgen Product Exposure 
Amgen Product Dose at time of Frequenc y Route conce ption 
Was the Amgen product (or study drug) discontinued? D Yes O No 
II yes. provide product (or study drug) stop date: mm __ ldd __ lyyyy __ 
Did the subject withdraw from the study? D Yes D No 
S. Pregnancy Information 
Pregn ant female's last menstrua l period (LMP) mm ___ / dd _ _ / 'fYYY ___ _ 
Estimated date of delivery mm ___ / dd ___ / 'fYYY __ 
If NIA, date of termination (actua l or planned) mm ___ / dd_/ yyyy ____ _ 
Has the pregnan t fema le alrea dy delivered? D Yes D No D Unknown D NIA 
If yes. provide date of delivery: mm ___ / dd ___ l 'fYYY __ _ 
Was the infant healthy? D Yes D No D Unknown D NIA Start Date 
mm __ /dd __ lyyyy __ 
If any Adverse Event was experienced by the infant. provide brief deta.i ls: _______________ _ 
Form Comnleted hv: 
Print N ame: _______________ _ Title: ________________ _ 
Signature: ________________ _ Date: ________________ _ 
FORM-115 199 Version 1.0 Erfeclive Date : 24-Seol-2018 
Product:  AMG 592  
Protocol Number:  20170103  
Date:  25 June 2020  Page 91 of 97 
CONFIDENTIAL   Figure 12-2.  Pregnancy and Lactation Notification Worksheet  
 
Approved  
  Amgon Proprietary -Conlidenti31 
AIVGEN • Lactati on Notification Form 
Study Design: C2l lnterventiona l O Observational (If Observational: 0 Prospec tive O Relrospective) 
2. Contact Information 
Investigato r Name_____________________ Site# ____________ _ 
Phone (__) ________ _ Fax.._ _ _,_ ________ _ Email ____________ _ 
Institution ________________________________________ _ 
4. Amgen Product Exposure 
Amgen Product Dose at time of Frequency Route breast feedinq 
Was the Amgen product (or study drug) discon tinued? O Yes O No 
If yes, provi de product (or study drug) stop date: mm __ ldd __ /yyyy __ 
Did the subject withdraw from the study? O Yes O No 
5. Breast Feeding Information Start Date 
mm__J dd_/yyyy __ 
Did the motl1er breasttee<J or provide the infant with pumped breast milK While active ly taKing an Amgen product? 0 Yes O No 
If No, provide stop date: mm ___ /dd ___ /yyyy ___ _ 
Infant date of birth: mm ___ ldd ___ lyyyy __ _ 
Infant gender : 0 Female O Male 
Is the infant healthy? 0 Yes O No O UnKnown O NIA 
If any Adverse Event was experienced by the mother or the infant, provi de br ief details: _______________ _ 
form Completed by 
Print Name: _______________ _ Title: ________________ _ 
Signature: ________________ _ Date : ________________ _ 
FORM -115201 Version 1.0 Ettect ive Date, 24-Sept -2018 
Product:  AMG 592  
Protocol Number:  20170103  
Date:  25 June 2020  Page 92 of 97 
CONFIDENTIAL   Appendix 6 .  Sample Storage and Destruction  
Any blood sample collected according to the Schedule of Activities ( Table  2-1 and Table 
2-2) c an be analyzed for any of the tests outlined in the protocol and for any tests 
necessary to minimize risks to study subjects.  This includes testing to ensure analytical methods produce reliable and valid data throughout the course of the study.  This can 
also include, but is not limited to, investigation of unexpected results, incurred sample 
reanalysis, and analyses for method transfer and comparability.  
All samples and associated results  wi
 ll be coded prior to being shipped from the site for 
analysis or storage.  Samples will be tracked using a unique identifier that is assigned to 
the samples for the study.  Results are stored in a secure database to ensure 
confidentiality.  
If informed consent is provided by the subject, Amgen can do additional testing on remaining samples (ie, residual and back -up)
  to investigate and better understand the 
inflammatory conditions, the dose response and/or prediction of response to AMG 59 2, 
and characterize aspects of the molecule (eg, mechanism of action/target, metabolites).  Results from this analysis are to be documented and maintained but are not necessarily reported as part of this study.  Samples can be retained for up to 20 years.   
Since the evaluations are not expected to benefit the subject directly or to alter the 
treatment course, the results of pharmacogenetic, biomarker development, or other
  
exploratory studies are not placed in the subject’s medical record and are not to be 
made available to the s u bject, members of the family, the personal physician, or other 
third parties, except as specified in the informed consent.  
The subject retains the right to request that the sample material be destroyed by contacting the investigator.  Following the request from the subject, the investigator is to provide the sponsor with the required study and subject number so that any remaining blood
  samples and any other components from the cells can be located and 
destroyed.  Samples will be destroyed once all pr otocol- defined procedures are 
completed.  However, information collected from samples prior to the request for destruction, will be retained by Amgen. 
Approved  
  AMGEN~ 
Product:  AMG 592  
Protocol Number:  20170103  
Date:  25 June 2020  Page 93 of 97 
CONFIDENTIAL   The sponsor is the exclusive owner of any data, discoveries, or derivative materials from 
the sample materials and is responsible for the destruction of the sample(s) at the request of the subject through the investigator, at the end of the storage period, or as 
appropriate (eg, the scientific rationale for experimentation with a certain sample type no 
longer  justifies keeping the sample).  If a commercial product is developed from this 
r
esearch project, the sponsor owns the commercial product.  The subject has no 
commercial rights to such product and has no commercial rights to the data, information, 
discoveries, or derivative materials gained or produced from the sample.  See Appendix 
3 for subject confidentiality .  
Approved  
  AMGEN~ 
Product:  AMG 592  
Protocol Number:  20170103  
Date:  25 June 2020  Page 94 of 97 
CONFIDENTIAL   Appendix 7 .  Hepatotoxicity Stopping Rules:  Suggested Actions and Follow -up 
Assessments and Study Treatment Rechallenge Guidelines 
Subjects with abnormal hepatic laboratory values (ie, alkaline phosphatase [ALP], 
aspartate aminotransferase [AST], alanine aminotransferase [ALT], total bilirubin [TBL]) and/or international normalized ratio (INR) and/or signs/symptoms of hepatitis (as described below) may meet the criteria for withholding or permanent discontinuation of 
Amgen investigational product or other protocol-required therapies, as specified in the Guidance for Industry Drug-Induced Liver Injury:  Premarketing Clinical Evaluation, 
July 2009 .
 
Criteria for Withholding and/or Permanent Discontinuation of Amgen 
Invest igat
ional Product and Other Protocol-required Therapies due to Potential 
Hepatotoxicity  
The following stopping and/or withholding rules apply to subjects for whom another 
cause of their changes in liver biomarkers (TBL, INR and transaminases) has not been identified.  
Important alternative causes for elevated AST/ALT and/or TBL values include, but are 
not limited to: 
• Hepatobiliary tract disease 
• Viral hepatitis (eg, hepatitis A/B/C/D/E, Epstein-Barr Virus, cytomegalovirus, 
her
pes simplex virus, varicella, toxoplasmosis, and parvovirus)  
• Right sided heart failure, hypotension or any cause of hypoxia to the liver causing 
i
schemia 
• Exposure to hepatotoxic agents/drugs or hepatotoxins, including herbal and 
di
etary supplements, plants and mushrooms  
• Heritable disorders causing impaired glucuronidation (eg, Gilbert’s syndrome, 
C
rigler-Najjar syndrome) and drugs that inhibit bi lirubin (BIL) glucuronidation 
(eg, indinavir, atazanavir)  
• Alpha-one antitrypsin deficiency  
• Alcoholic hepatitis  
• Autoimmune hepatitis  
• Wilson’s disease and hemochromatosis  
• Nonalcoholic fatty liver disease including steatohepatitis  
• Non- hepatic causes (eg, rhabdomylosis, hemolysis)  
If investigational product(s)  is /are withheld, the subject is to be followed for possible 
drug-induced liver injury ( DILI ) according to recommendations in the last section of this 
appendix.  
Approved  
  AMGEN~ 
Product:  AMG 592  
Protocol Number:  20170103  
Date:  25 June 2020  Page 95 of 97 
CONFIDENTIAL   Rechallenge may be considered if an alternative cause for impaired liver tests (ALT, 
AST, ALP) and/or  elevated TBL, is discovered and the laboratory abnormalities resolve 
to normal or baseline (see next section in this appendix). 
Table 12-2 .  Condit ions for Withholding and/or Permanent Discontinuation of 
Amgen Investigational Product and Other Protocol-required Therapies due to 
Potential Hepatotoxicity  
Analyte  Temporary Withholding  Permanent Discontinuation  
TBL > 3 x ULN at any time > 2 x ULN 
  O
R 
INR -- > 1.5  x ULN (for subjects not on 
ant
icoagulation therapy)  
 OR AND  
AST/ALT  > 8 x ULN at any time 
> 
5 x ULN but < 8  x  ULN for ≥ 2 weeks  
> 5 x ULN but < 8  x ULN and unable to 
adhere to enhanced monitoring schedule  
> 3 x ULN with clinical signs or symptoms 
that are consistent with hepatitis (such as 
right upper quadrant pain/tenderness, 
fever, nausea, vomiting, and jaundice)  In the presence of no important 
alternative causes for elevated 
AST/ALT and/or TBL values  
> 3 x ULN (when baseline was <  U LN) 
 OR  
ALP > 8 x ULN at any time -- 
ALP = alkaline phosphatase; ALT = alanine aminotransferase; AST = aspartate aminotransferase;  
INR = international normalized ratio; TBL = total bilirubin; ULN = upper limit of normal  
Criteria for Rechallenge of Amgen Investigational Product and Other 
Protocol-required Therapies After Potential Hepatotoxicity  
The decision to rechallenge the subject is to be discussed and agreed upon 
unanimously by the subject, investigator, and Amgen.  
If signs or symptoms recur with rechallenge, then investigational product is  to be 
permanently discontinued.  Subjects who clearly meet the criteria for permanent 
discontinuation (as described in Table 12-2 ) ar e never to be rechallenged. 
Approved  
  AMGEN~ 
Product:  AMG 592  
Protocol Number:  20170103  
Date:  25 June 2020  Page 96 of 97 
CONFIDENTIAL   Drug -induced Liver Injury Reporting and Additional Assessments 
Reporting 
To facilitate appropriate monitoring for signals of DILI, cases of concurrent AST or ALT 
and TBL and/or INR elevation, according to the criteria specified in the above, require the following: 
• The ev ent is to be reported to Amgen as a serious adverse event within 24 hour
 s of 
discovery or notification of the event (ie, before additional etiologic investigations 
have been concluded)  
• The appr opr iate case report form ( CRF) (eg, Event CRF) that captures information 
necessary to facilitate the evaluation of treatment-emergent liver abnormalities is to be completed and sent to Amgen  
Other events of hepatotoxicity and potential DILI are to be reported as serious adverse 
events if they meet the criteria for a serious adverse event defined in Appendix 4.  
Additional Clinical Assessments and Observation 
All subjects in whom investigational product(s) or protocol -r
 equired therapies is/are 
withheld (either permanently or conditionally) due to potential DILI as specified in  Ta ble 
12-2 or who experience AST or ALT elevations >  3 x upper limit of normal (ULN) or 
2-fold increases above baseline values for subjects with elevated values before drug are 
to undergo a period of “close observation” until abnormalities return to normal or to the subject’s baseline levels.   
Assessments that are to be performed during this period include:  
• Repeat AST, ALT, ALP, BIL (
 total and direct), and INR within 24 hours  
• In cases of TBL > 2 x  ULN or INR > 1.5, retesting of liver tests, BIL (total and 
direct), and INR is to be performed every 24 hours until laboratory abnormalities 
improve 
Testing frequency of the above laboratory tests may decrease if the abnormalities 
stabilize or the investigational product(s) or protocol -r equired therapies has/have been 
discontinued AND the subject is asymptomatic. 
Initiate investigation of alternative causes for elevated AST or ALT and/or elevated TBL.  
The following are to be considered depending on the clinical situation:  
• Complete blood count with differential to assess for eosinophilia  
• Serum total immunoglobulin G, antinuclear antibody, anti smooth muscle antibody, 
and l
iver kidney microsomal antibody-1 to assess for autoimmune hepatitis  
• Serum acetaminophen (paracetamol) levels  
Approved  
  AMGEN~ 
Product:  AMG 592  
Protocol Number:  20170103  
Date:  25 June 2020  Page 97 of 97 
CONFIDENTIAL   • A more detailed history of:  
o Prior and/or concurrent diseases or illness 
o Exposure to environmental and/or industrial chemical agents  
o Symptoms (if applicable) including right upper quadrant pain, 
hy
persensitivity -t ype reactions, fatigue, nausea, vomiting and fever  
o Prior and/or concurrent use of alcohol, recreational drugs and special diets  
o Concomitant use of medications (including non-prescription medicines and 
her
bal and dietary supplements), plants, and mushrooms  
• Viral serologies  
• Creatine phosphokinase (CPK), haptoglobin, lactate dehydrogenase, and peripheral 
bl
ood smear  
• Appropriate liver imaging if clinically indicated  
• Appropriate blood sampling for pharmacokinetic analysis if this  has  not already 
been collected 
• Hepatology consult (liver biopsy may be considered in consultation with a 
hepatol
ogist)  
Follow the subject and the laboratory tests (ALT, AST, TBL, and INR ) until all laboratory 
abnormalities return to baseline or normal or considered stable by the investigator.  The 
“close observation period” is to continue for a minimum of 4 week s after discontinuation 
of all investigational product(s) and protocol -r equired therapies. 
The potential DILI event and additional information such as m edical history, concomitant 
medications and laboratory results must be captured in the corresponding CRFs.  
Approved  
  AMGEN~ 
Product :  AMG 592  
Protocol Number:  20170103  
Date:  25 June 2020  Page 1 of 1 
CONFIDENTIAL    Superseding Amendment 5 
Protocol Title:  A Randomized, Double-blind, Placebo-controlled Phase 1b Study 
to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and 
Immunogenicity of Multiple Ascending Subcutaneous Doses of AMG 592 in 
Subjects With Systemic Lupus Erythematosus 
 
Amgen Protocol Number 20170103 
 
 
Amendment Date: 23 April 2020 
Superseding Amendment 
Date: 25 June 2020 
Rationale: 
The current protocol (amendment 4) is designed as a seamless phase 1b/2a study to 
evaluate the safety and efficacy of AMG 592 in subjects with active systemic lupus 
erythematosus.   
The phase 2a will now be converted into a phase 2b.  Due to the complexity of the new 
phase 2b design, it was decided that splitting  the study into 2 protocols would avoid 
logistical problems for clinical development and clinical operations (vendors, etc).  
Having separate protocols also alleviates any possibility of unblinding in a shared 
database.  
The following changes were made to the superseding protocol dated 25 June 2020:  
It was noted that in the amendment process for protocol amendment 1 , the exploratory 
endpoints for the phase 1b portion of the study were accidentally deleted.  These have 
been added back to support the analyses of these endpoints . 
Approved  
  ANIGEN® 
Product:  AMG 592  
Protocol Number:  20170103  
Date:  23  April 2020  Page 1 of 1 
CONFIDENTIAL    Amendment 5 
Protocol Title:  A Randomized, Double- blind, Placebo- controlled Phase 1b Study 
to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and 
Immunogenicity of Multiple Ascending Subcutaneous Doses of AMG 592 in 
Subjects With Systemic Lupus Erythematosus 
 
Amgen Protocol Number 20170103  
 
 
Amendment Date:  23 April 2020  
Rationale:  
The current protocol (amendment 4) is designed as a seamless phase 1b/2a study to 
evaluate the safety and efficacy of AMG 592 in subjects with active systemic lupus erythematosus (SLE) with inadequate response to standard of care therapy.   
The study has become part of the Food and Drug Administration ( FDA) Complex 
Innovative Design (CID) pilot program.  With the opportunity to implement a CID to the SLE de velopment program, the phase 2a is now a phase 2b.  Due to the complexity of 
the new phase 2b design, it was decided that split the study into 2 protocols would avoid logistical problems for clinical development and clinical operations (vendors, etc).  Having separate protocols also alleviates any possibility of unblinding in a shared 
database.  
In addition, it was noted that in the amendment process for protocol amendment 1, the exploratory endpoints for the phase 1b portion of the study were accidentally deleted.  These have been added back to the protocol, with some additional text to support the analyses of these endpoints.  
Approved  
  ANIGEN® 
Product:  AMG 592  
Protocol Number:  20170103  
Date:  24 February 2020  Page 1 of 4 
CONFIDENTIAL   Superseding Amendment 4 
Protocol Title:  A Phase 1b/2a Study to Evaluate the Safety and Efficacy of 
AMG  592 in Subjects With Active Systemic Lupus Erythematosus With Inadequate 
Response to Standard of Care Therapy  
 
Amgen Protocol Number (AMG 592) 20170103 
Study ID: [REMOVED] 
EudraCT Number 2017-002564-40 
 
Amendment Date: 24 February 2020 
Rationale: 
This superseding amendment is to address administrative details that were erroneously 
included in protocol amendment 4 dated 06 February 2020. 
Approved  
  ANIGEN® 
Product:  AMG 592 
Protocol Number:  20170103  
Date:  06 February 2020  Page 1 of 20 
CONFIDENTIAL   Amendment 4 
Protocol Title:  A Phase 1b/2a Study to Evaluate the Safety and Efficacy of 
AMG  592 in Subjects With Active Systemic Lupus Erythematosus With Inadequate 
Response to Standard of Care Therapy  
 
Amgen Protocol Number (AMG 592) 20170103  
Study ID: [REMOVED] 
EudraCT Number 2017 -002564- 40 
 
Amendment Date:  06 February 2020 
Rationale:  
This protocol is being amended to add 2 additional dosing cohorts to the phase 1b part 
of the protocol in order to investigate whether treatment with higher doses of AMG 592 is safe and may result in greater Treg expansion with continued maintenance of selectivity. This amendment also allows re- enrollment of previously enrolled study subjects provided 
they meet additional entry criteria.  
Approved  
  AMGEN® 
Not Approved  
  Product:  AM G 592  
Protocol Number:  20170103  
Date:  18 N ovember  2019  Page 1 of 6 
CONFIDENTIAL   Amendment 3 
Protocol Title:  A Phase 1b/2a Study to Evaluate the Safety and Efficacy of 
AMG  592 in Subjects W ith Active Systemic Lupus Erythematosus W ith Inadequate 
Response to Standard of Care Therapy  
 
Amgen Protocol Number (AMG 592) 20170103 
Study ID: [REMOVED] 
EudraCT Number :  2017-002564-40 
 
Amendment Date: 18 November 2019 
Rationale: 
This protocol is being amended to add language for home healthcare provided services 
and to remove Amgen retired template language in regards to self-evident corrections.  
ANIGEN® 
Product:  AMG 592 
Protocol Number:  201701 03 
Date:   12 June 2019  Page 1 of 21 
CONFIDENTIAL   Amendment 2 
Protocol Title:  A Phase 1b/2a Study to Evaluate the Safety and Efficacy of  
AMG 592 in Subjects With Active Systemic Lupus Erythematosus With Inadequate 
Response to Standard of Care Therapy  
 
Amgen Protocol Number : AMG 592 20170103  
 
Amendment Da te: 12 June 2019  
Rationale:  
The rationale for this protocol amendment is:  
1. To update the phase 1b sample size language throughout the protocol to allow 
flexibility for expansion and/or addition of cohorts per DLRM recommendation, for 
replacement of subjects who discontinue investigational drug product prior to 
completing week 4 of the study and to allow enrollment of additional eligible screened subjects in each cohort.  
2. To allow subjects to meet entry criteria with a history of positive ANA and anti- dsDNA 
antibody rather than positive results at screening because these tests may wax and wane in SLE patients.  
3. To update the Risk Assessments section of the protocol to align with recent change 
to the Investigator’s Brochure.  
4. To update the dose for cohort 3, from  µg   to  µg  in order to allow 
exploration of a wider dose range in the phase 1b part of the study. Administration of 
the  µg  dose to all subjects in cohort 2 has been completed through the 
DLRM evaluat ion period.  Blinded review has  revealed no concerning safety signals 
and investigational product (AMG 592 or placebo) has been generally well -tolerated.  
These data provide justification for consideration of dose escalation to the  µg 
 dose.  
Approved  
  ANIGEN~ 

Product:  AMG 592 
Protocol Number:  20170103  
Date:  26 July 2018 Page 1of 3
CONFIDENTIALAmendmen t 1
Protocol Title:  A Phase 1b/2a Study to Evaluate the Safety and Efficacy of 
AMG 592 in Subjects With A ctive Systemic Lupus Erythematosus With Inadequate 
Response to Standard of Care Therapy
Amgen Protocol Number (AMG 592) 20170103
Study ID: [REMOVED]
EudraCT Number 2017 -002564 -40
Amendment Date: 26July 2018
Rationale:
This protocol is being amended to change subject urine drug/alcohol testing, during 
screening, from the local laboratory to the central laboratory.
Approved  
  AMGEN® 